_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
503232568,7/15/2014 14:53:29,,1323607087,7/15/2014 14:53:06,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 14:59:19,,1323609370,7/15/2014 14:58:55,clixsense,1,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CONTRAINDICATES],[CONTRAINDICATES],failure in,na,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 14:59:49,,1323609545,7/15/2014 14:59:19,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],ERYTHROMYCIN failure in SYPHILIS in pregnant woman.,N/A,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 15:19:25,,1323619147,7/15/2014 15:18:38,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],the treatment of,N/A,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 15:43:32,,1323636410,7/15/2014 15:43:10,neodev,1,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],failure treatment,N/A,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 15:45:01,,1323637665,7/15/2014 15:44:25,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treatment,n\a,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 17:14:58,,1323724693,7/15/2014 17:14:24,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],ERYTHROMYCIN failure in the treatment of SYPHILIS,n/a,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 17:43:23,,1323746174,7/15/2014 17:43:07,sendearnings,1,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],treatment,n/a,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 18:11:01,,1323766073,7/15/2014 18:10:42,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],ERYTHROMYCIN treatment SYPHILIS,N/A,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 18:14:57,,1323767288,7/15/2014 18:14:24,clixsense,1,24858196,USA,PA,Kingston,96.253.217.126,[TREATS],[TREATS],failure treatment,N/A,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 18:58:12,,1323786690,7/15/2014 18:58:08,prodege,1,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 19:02:55,,1323789635,7/15/2014 19:02:36,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treatment,not applicable,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 19:17:58,,1323797285,7/15/2014 19:15:57,gifthulk,1,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ERYTHROMYCIN failure in SYPHILIS,N/A,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 22:27:07,,1323874412,7/15/2014 22:26:33,clixsense,1,19500241,USA,NC,Greensboro,174.98.255.13,[NONE],[NONE],N/A,The words are not related.,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232568,7/15/2014 22:27:18,,1323874473,7/15/2014 22:26:55,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],ERYTHROMYCIN failure treatment of SYPHILIS,N/A,41,0,48,12,1,RO-may_treat,907476-FS1,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
503232569,7/15/2014 14:53:20,,1323607046,7/15/2014 14:53:06,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],caused by,N/A,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 14:57:54,,1323608818,7/15/2014 14:57:24,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],caused,na,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 15:35:16,,1323630174,7/15/2014 15:35:02,quickrewards,1,20452113,USA,NY,Port Henry,108.176.206.207,[CAUSES],[CAUSES],caused by,N/A,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 15:46:10,,1323638505,7/15/2014 15:45:57,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],caused,n/a,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 15:49:42,,1323641055,7/15/2014 15:49:14,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],caused by,n/a,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 16:05:00,,1323653017,7/15/2014 16:04:24,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",is caused by,N/A,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 16:48:56,,1323699607,7/15/2014 16:47:45,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],caused by,n/a,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 17:14:58,,1323724687,7/15/2014 17:14:37,neodev,1,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],caused by,na,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 17:58:06,,1323760749,7/15/2014 17:57:47,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],PAIN caused by ENDOMETRIOSIS,N/A,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 17:59:19,,1323761463,7/15/2014 17:59:02,prodege,1,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],caused by,n/a,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 18:25:10,,1323771157,7/15/2014 18:24:47,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],caused,n/a,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 18:29:19,,1323772939,7/15/2014 18:28:51,prodege,1,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],PAIN is caused by ENDOMETRIOSIS,n/a,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 18:57:25,,1323786173,7/15/2014 18:57:21,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 19:18:03,,1323797339,7/15/2014 19:17:38,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",caused by,not applicable,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232569,7/15/2014 20:53:06,,1323835598,7/15/2014 20:52:48,instagc,1,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],is caused by,N/A,36,54,39,67,-1,RO-has_definitional_manifestation,904760-FS1,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
503232570,7/15/2014 15:00:29,,1323609824,7/15/2014 15:00:14,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],assessed,Na,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 15:26:41,,1323623984,7/15/2014 15:26:27,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was assessed by,N/A,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 15:35:35,,1323630439,7/15/2014 15:35:17,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assessed by,N/A,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 15:40:07,,1323633903,7/15/2014 15:39:20,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was assessed by,N/A,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 16:39:13,,1323688742,7/15/2014 16:38:52,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assessed,N/A,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 16:40:36,,1323690417,7/15/2014 16:40:07,zoombucks,1,9383666,USA,IN,Fishers,108.71.210.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was assessed by,ha,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 16:56:24,,1323707834,7/15/2014 16:55:21,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assessed by,N/A,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 17:12:01,,1323722913,7/15/2014 17:11:31,tremorgames,1,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],susceptibility,N/A,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 17:21:12,,1323727872,7/15/2014 17:20:15,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was assessed by,na,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 17:24:22,,1323729445,7/15/2014 17:23:41,clixsense,1,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was assessed,N/A,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 17:43:15,,1323745987,7/15/2014 17:42:42,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],susceptibility was assessed by,N/A,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 18:18:39,,1323768648,7/15/2014 18:17:43,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge,n/a,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 18:26:54,,1323771845,7/15/2014 18:26:38,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE,N/A,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 18:57:04,,1323785966,7/15/2014 18:56:59,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232570,7/15/2014 19:12:49,,1323794552,7/15/2014 19:12:22,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was assessed,not applicable,0,54,21,63,1,RO-may_diagnose,906665-FS1,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
503232571,7/15/2014 14:54:00,,1323607289,7/15/2014 14:53:25,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",is,N/A,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 14:56:29,,1323608298,7/15/2014 14:55:59,vivatic,1,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],antipsychotic agent,N/A,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 15:03:54,,1323611568,7/15/2014 15:03:36,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],efficacy symptoms,Na,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 15:18:47,,1323618774,7/15/2014 15:18:21,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],antipsychotic agent with efficacy for symptoms of SCHIZOPHRENIA,N/A,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 15:25:16,,1323623025,7/15/2014 15:25:07,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[SYMPTOM],[SYMPTOM],symptoms of,N/A,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 15:44:52,,1323637582,7/15/2014 15:44:15,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],atypical agent,N/A,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 15:50:29,,1323641614,7/15/2014 15:50:07,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],antipsychotic agent with efficacy,n/a,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 16:43:06,,1323693061,7/15/2014 16:42:38,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SYMPTOM],[SYMPTOM],symptoms,N/A,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 16:52:13,,1323703300,7/15/2014 16:51:36,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],RISPERIDONE for both positive and negative symptoms of SCHIZOPHRENIA,"Again, no Treated by option.",104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 17:33:53,,1323737465,7/15/2014 17:33:24,clixsense,1,21917173,CAN,"","",24.71.41.51,[TREATS],[TREATS],with efficacy,n/a,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 18:22:38,,1323770241,7/15/2014 18:21:45,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[TREATS],[TREATS],RISPERIDONE is an atypical antipsychotic agent with efficacy for symptoms of SCHIZOPHRENIA,n/a,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 18:55:17,,1323785073,7/15/2014 18:54:41,neodev,1,21405167,USA,MD,Glen Burnie,69.137.237.73,[SYMPTOM],[SYMPTOM],symptoms of,N/A,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 19:07:31,,1323791697,7/15/2014 19:07:06,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SYMPTOM],[SYMPTOM],symptoms,not applicable,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 19:54:04,,1323811810,7/15/2014 19:52:39,elite,1,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],efficacy for both positive and negative symptoms,N/A,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232571,7/15/2014 20:40:29,,1323830631,7/15/2014 20:38:24,bitcoinget,1,21384744,USA,MN,Saint Paul,75.73.34.174,[OTHER],[OTHER],agent for symptoms of,N/a,104,0,116,11,1,RO-may_treat,907998-FS1,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
503232572,7/15/2014 14:51:10,,1323606251,7/15/2014 14:50:59,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],erythromycin,N/A,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 14:52:31,,1323606654,7/15/2014 14:52:07,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 15:04:34,,1323611827,7/15/2014 15:04:17,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treatment,Na,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 15:51:39,,1323642570,7/15/2014 15:51:23,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment of,n/a,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 16:13:42,,1323659930,7/15/2014 16:13:29,clixsense,1,20614047,USA,ID,Priest River,174.32.160.124,[LOCATION],[LOCATION],of erythromycin,asd,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 16:18:53,,1323664497,7/15/2014 16:18:29,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],for treatment of,N/A,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 16:38:15,,1323687543,7/15/2014 16:37:25,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment,n/a,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 17:01:31,,1323713699,7/15/2014 17:00:47,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[TREATS],[TREATS],treatment,N/A,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 17:15:56,,1323725180,7/15/2014 17:15:37,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the,N/A,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 17:44:32,,1323747239,7/15/2014 17:44:18,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],PERTUSSIS: the ERYTHROMYCIN,N/A,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 18:55:27,,1323785141,7/15/2014 18:55:22,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 19:06:07,,1323791008,7/15/2014 19:05:28,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treatment,not applicable,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 21:40:52,,1323854930,7/15/2014 21:40:23,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],erythromycin for treatment of PERTUSSIS:,n/a,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 22:04:47,,1323864213,7/15/2014 22:04:34,neodev,1,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PERTUSSIS:,NONE,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232572,7/15/2014 22:17:45,,1323870065,7/15/2014 22:17:21,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],treatment of PERTUSSIS: ERYTHROMYCIN Study Group.,N/A,95,110,103,122,1,RO-may_treat,907514-FS1,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
503232573,7/15/2014 14:49:33,,1323605640,7/15/2014 14:48:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],GROUP,N/A,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 14:49:36,,1323605653,7/15/2014 14:49:28,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],test,N/A,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 14:55:31,,1323607847,7/15/2014 14:54:45,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CONTRAINDICATES],[CONTRAINDICATES],was test,N/A,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 15:05:20,,1323612139,7/15/2014 15:04:51,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],no difference,Na,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 15:15:56,,1323617270,7/15/2014 15:15:27,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Two unrelated conditions.,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 15:23:25,,1323621826,7/15/2014 15:23:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the,N/A,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 15:41:24,,1323634751,7/15/2014 15:40:38,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[OTHER],[OTHER],between the and the,n/a,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 16:05:55,,1323653769,7/15/2014 16:04:53,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],difference,asd,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 16:40:25,,1323690200,7/15/2014 16:39:39,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[NONE],[NONE],N/A,two distinct groups are contrasted,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 16:50:44,,1323701640,7/15/2014 16:50:19,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the,N/A,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 16:51:27,,1323702388,7/15/2014 16:50:42,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],ALLERGY and NON ALLERGY,n/a,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 17:57:19,,1323760165,7/15/2014 17:56:38,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[CONTRAINDICATES],[CONTRAINDICATES],between NON,n/a,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 18:35:34,,1323775013,7/15/2014 18:34:53,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[NONE],[NONE],n/a,No relation found.,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 18:53:52,,1323784227,7/15/2014 18:53:15,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[NONE],[NONE],N/A,Two separate groups,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232573,7/15/2014 19:14:08,,1323795162,7/15/2014 19:13:22,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],irritation test,not applicable,136,107,152,127,-1,RO-cause_of,900444-FS1,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
503232574,7/15/2014 14:44:22,,1323603546,7/15/2014 14:43:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],LUNG,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 14:50:27,,1323605959,7/15/2014 14:50:07,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],chest,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 15:21:00,,1323620205,7/15/2014 15:20:23,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],and in,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 15:27:41,,1323624714,7/15/2014 15:27:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 15:38:46,,1323632925,7/15/2014 15:38:24,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/a,Separate terms,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 16:20:11,,1323665908,7/15/2014 16:19:17,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[NONE],[NONE],N/A,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 16:20:12,,1323665945,7/15/2014 16:18:16,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],particular disease,asd,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 16:48:30,,1323699195,7/15/2014 16:47:40,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,they are two different things,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 17:46:20,,1323749034,7/15/2014 17:46:11,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],CELLS;,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 18:00:02,,1323761744,7/15/2014 17:59:23,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[MANIFESTATION] [LOCATION],"[LOCATION]
[MANIFESTATION]",FREE LUNG CELLS; in BRONCHIAL CARCINOMA,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 18:39:19,,1323776761,7/15/2014 18:38:53,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],and in,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 19:02:35,,1323789466,7/15/2014 19:01:45,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,There are no words that relate them together.,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 19:30:33,,1323802904,7/15/2014 19:29:56,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],testing function of FREE LUNG CELLS; in BRONCHIAL CARCINOMA,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 20:14:56,,1323820302,7/15/2014 20:14:25,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in,N/A,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232574,7/15/2014 22:02:32,,1323863231,7/15/2014 22:02:14,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],morphology,NONE,265,289,279,308,1,RO-disease_has_primary_anatomic_site,902226-FS1,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
503232575,7/15/2014 14:58:48,,1323609144,7/15/2014 14:58:23,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was diagnosed.,N/A,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 15:20:54,,1323620129,7/15/2014 15:20:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was diagnosed.,N/A,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 16:08:55,,1323656099,7/15/2014 16:08:13,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[TREATS],[TREATS],HEMOPHAGOCYTOSIS,asd,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 16:34:39,,1323683214,7/15/2014 16:34:18,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed.,N/A,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 16:43:30,,1323693605,7/15/2014 16:43:10,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],diagnosed.,N/A,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 17:11:47,,1323722733,7/15/2014 17:10:59,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEMOPHAGOCYTOSIS HEMOPHAGOCYTIC,na,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 18:28:38,,1323772675,7/15/2014 18:28:33,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],hyperferritinemia,n/a,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 18:28:50,,1323772732,7/15/2014 18:27:52,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],"with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",n/a,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 19:11:43,,1323794001,7/15/2014 19:11:17,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed.,not applicable,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 21:45:00,,1323856346,7/15/2014 21:44:30,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],"HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",n/a,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 22:05:37,,1323864567,7/15/2014 22:04:59,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[SYMPTOM],[SYMPTOM],(hemoglobin:,NONE,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 22:16:19,,1323869404,7/15/2014 22:15:36,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"in the bone marrow, was diagnosed.",n/a,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 22:32:35,,1323877059,7/15/2014 22:31:44,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HEMOPHAGOCYTOSIS HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.,N/A,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 22:47:45,,1323884422,7/15/2014 22:46:09,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"with HEMOPHAGOCYTOSIS bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosed.",associated with,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232575,7/15/2014 23:07:16,,1323895013,7/15/2014 23:05:07,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[DIAGNOSE_BY_TEST_OR_DRUG] [OTHER],"[DIAGNOSE_BY_TEST_OR_DRUG]
[OTHER]","HEMOPHAGOCYTOSIS in bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",N/A,159,196,174,230,1,RO-disease_has_finding,901897-FS1,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
503232576,7/15/2014 15:27:43,,1323624740,7/15/2014 15:27:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 15:31:37,,1323627551,7/15/2014 15:30:21,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]","QT prolongation, rate rhythm composite,",[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [SYMPTOM],216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 15:49:07,,1323640591,7/15/2014 15:48:21,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 16:08:08,,1323655486,7/15/2014 16:07:28,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[TREATS],[TREATS],revealed that QT,asd,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 17:17:32,,1323726042,7/15/2014 17:17:15,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 17:43:27,,1323746226,7/15/2014 17:43:16,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 17:57:10,,1323759977,7/15/2014 17:56:20,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]","rate rhythm composite,",n/a,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 17:59:47,,1323761621,7/15/2014 17:58:42,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TACHYCARDIA and TORSADES DE POINTES,N/A,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 18:30:23,,1323773292,7/15/2014 18:29:50,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TACHYCARDIA and TORSADES DE POINTES,N/A,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 19:14:47,,1323795507,7/15/2014 19:14:09,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,There is no relation between the two.,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 19:51:23,,1323810883,7/15/2014 19:50:48,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 20:49:34,,1323834258,7/15/2014 20:48:56,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],9 clusters affecting TACHYCARDIA TORSADES DE POINTES,N/A,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 21:41:20,,1323855113,7/15/2014 21:40:53,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],TACHYCARDIA and TORSADES DE POINTES affecting the heart muscle,n/a,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 22:03:28,,1323863593,7/15/2014 22:01:20,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They appear in the same list but have no other relation.,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232576,7/15/2014 22:43:17,,1323882516,7/15/2014 22:41:19,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[IS_A],[IS_A],TACHYCARDIA and TORSADES DE POINTES,N/A,216,232,226,251,-1,RO-has_definitional_manifestation,904648-FS1,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, TACHYCARDIA and TORSADES DE POINTES and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",TACHYCARDIA,TORSADES DE POINTES
503232577,7/15/2014 14:48:16,,1323605188,7/15/2014 14:48:06,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],verruciformis,N/A,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 14:49:59,,1323605827,7/15/2014 14:49:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with minimal,N/A,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 14:52:05,,1323606545,7/15/2014 14:51:36,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],with minimal,N/A,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 15:32:40,,1323628372,7/15/2014 15:32:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with minimal,N/a,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 15:34:45,,1323629846,7/15/2014 15:32:59,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],with minimal,N/A,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 16:46:31,,1323696996,7/15/2014 16:46:11,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],with,N/A,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 16:47:14,,1323697909,7/15/2014 16:46:39,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],with,n/a,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 17:30:43,,1323734452,7/15/2014 17:30:07,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 18:09:26,,1323765574,7/15/2014 18:08:48,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS,N/A,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 20:40:53,,1323830801,7/15/2014 20:40:07,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],with minimal HYPERKERATOSIS,N/A,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 21:48:17,,1323857456,7/15/2014 21:47:36,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],with minimal HYPERKERATOSIS,n/a,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 22:01:27,,1323862784,7/15/2014 22:01:15,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[SYMPTOM],[SYMPTOM],verruciformis,NONE,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 22:30:46,,1323876176,7/15/2014 22:29:48,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VERRUCA PLANA TYPE LESION with HYPERKERATOSIS,N/A,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 23:03:13,,1323892371,7/15/2014 23:02:07,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],VERRUCA PLANA TYPE LESION minimal HYPERKERATOSIS,Manifestation,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232577,7/15/2014 23:13:20,,1323898415,7/15/2014 23:11:44,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS,N/A,115,76,128,101,-1,RO-disease_has_finding,901815-FS1,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
503232578,7/15/2014 14:45:15,,1323603922,7/15/2014 14:44:35,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",caused by with,N/A,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 15:02:58,,1323611137,7/15/2014 15:02:32,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,"Different, unrelated conditions",217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 15:21:21,,1323620469,7/15/2014 15:20:40,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],aetiologies,N/A,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 15:23:30,,1323621904,7/15/2014 15:22:23,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[NONE],[NONE],N/A,"They are two separate diseases that were having the same treatment tested on them, but are not directly related themselves.",217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 15:25:28,,1323623233,7/15/2014 15:25:16,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(six patients with one with,N/A,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 15:38:25,,1323632616,7/15/2014 15:37:43,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,examples of diseases with the same treatment,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 16:07:07,,1323654715,7/15/2014 16:05:02,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],chorea caused by various aetiologies,N/A,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 16:17:12,,1323663031,7/15/2014 16:16:22,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[NONE],[NONE],N/A,N/A,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 16:47:29,,1323698075,7/15/2014 16:47:15,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],one with,N/A,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 17:14:47,,1323724576,7/15/2014 17:14:13,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],one with,N/A,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 17:41:37,,1323744613,7/15/2014 17:40:37,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was investigated,N/A,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 17:47:36,,1323750234,7/15/2014 17:47:25,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],one with,N/A,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 17:59:47,,1323761627,7/15/2014 17:59:20,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[NONE],[NONE],n/a,both are diseases but no relationship is shown,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 18:57:20,,1323786131,7/15/2014 18:57:13,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232578,7/15/2014 19:11:16,,1323793710,7/15/2014 19:10:09,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,The two diseases are not related. One patient just has both.,217,187,222,207,1,RO-has_manifestation,906390-FS1,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with HUNTINGTON'S DISEASE one with CHOREA acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",CHOREA,HUNTINGTON'S DISEASE
503232579,7/15/2014 14:40:31,,1323602124,7/15/2014 14:40:19,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],alternative analgesic,na,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 14:57:03,,1323608517,7/15/2014 14:56:44,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],common analgesic,na,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 14:58:58,,1323609214,7/15/2014 14:58:39,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],PARACETAMOL common analgesic for MINOR PAIN,N/A,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 15:02:01,,1323610609,7/15/2014 15:01:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],was,N/A,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 15:26:52,,1323624152,7/15/2014 15:26:19,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",alternative analgesic for,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 15:43:09,,1323636106,7/15/2014 15:42:45,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],common analgesic,N/A,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 16:53:46,,1323704850,7/15/2014 16:53:26,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],common alternative analgesic,n/a,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 17:09:33,,1323721084,7/15/2014 17:09:14,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],for MINOR PAIN,treated by,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 17:19:04,,1323726729,7/15/2014 17:18:35,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PREVENTS],[PREVENTS],analgesic,N/A,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 17:40:35,,1323743663,7/15/2014 17:40:03,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],common alternative,N/A,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 17:43:06,,1323745862,7/15/2014 17:42:39,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],common alternative analgesic,n/a,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 17:54:08,,1323756808,7/15/2014 17:51:16,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[OTHER],[OTHER],analgesic for,N/A,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 18:28:31,,1323772635,7/15/2014 18:28:24,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SIDE_EFFECT],[SIDE_EFFECT],analgesic,n/a,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 18:36:44,,1323775525,7/15/2014 18:34:42,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[OTHER] [TREATS],"[TREATS]
[OTHER]",alternative analgesic for,It helps against the pain like another medication,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232579,7/15/2014 19:31:01,,1323803070,7/15/2014 19:30:34,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],PARACETAMOL was the most common analgesic for MINOR PAIN,N/A,74,0,83,11,1,RO-may_treat,908294-FS1,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
503232580,7/15/2014 14:50:37,,1323606006,7/15/2014 14:50:28,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],VIII,N/A,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 14:54:24,,1323607478,7/15/2014 14:54:14,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treated with,N/A,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 15:01:24,,1323610295,7/15/2014 15:01:10,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII),N/A,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 15:03:34,,1323611416,7/15/2014 15:03:22,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treated,Na,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 15:09:51,,1323614126,7/15/2014 15:09:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treated with,N/A,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 15:35:01,,1323630013,7/15/2014 15:34:47,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],treated with,N/A,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 15:40:37,,1323634245,7/15/2014 15:40:09,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treated with,n\a,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 15:54:39,,1323644857,7/15/2014 15:54:21,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treated with,n/a,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 17:22:14,,1323728405,7/15/2014 17:21:14,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],patients treated with,na,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 17:33:08,,1323736725,7/15/2014 17:32:20,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],treated,N/A,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 17:55:10,,1323757799,7/15/2014 17:54:50,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],treated with,is treated by,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 18:28:56,,1323772760,7/15/2014 18:28:48,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],treated,n/a,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 18:50:59,,1323782689,7/15/2014 18:50:46,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],treated with,N/A,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 18:55:53,,1323785374,7/15/2014 18:55:48,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232580,7/15/2014 19:09:19,,1323792836,7/15/2014 19:09:00,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treated with,not applicable,0,36,12,61,1,RO-may_treat,908174-FS1,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
503232581,7/15/2014 14:53:04,,1323606947,7/15/2014 14:52:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],HEADACHE,N/A,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 14:59:29,,1323609387,7/15/2014 14:59:06,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],cluster,N/A,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 15:07:07,,1323612992,7/15/2014 15:06:37,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],the primary headache syndromes include,N/A,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 15:25:33,,1323623299,7/15/2014 15:25:09,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],primary headache syndromes,N/A,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 16:42:11,,1323692041,7/15/2014 16:41:49,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[IS_A],[IS_A],"HEADACHE HEADACHE,",N/A,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 17:07:41,,1323719602,7/15/2014 17:07:04,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[IS_A],[IS_A],HEADACHE,na,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 17:23:39,,1323729090,7/15/2014 17:21:41,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 17:24:24,,1323729468,7/15/2014 17:23:15,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[IS_A],[IS_A],"HEADACHE,",n/a,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 18:22:26,,1323770044,7/15/2014 18:22:09,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A],[IS_A],"HEADACHE HEADACHE,",N/A,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 18:29:32,,1323773000,7/15/2014 18:29:28,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],"analgesics,",n/a,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 19:13:21,,1323794807,7/15/2014 19:12:50,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,not applicable,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 20:40:06,,1323830434,7/15/2014 20:39:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],"TENSION TYPE HEADACHE HEADACHE,",N/A,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 21:39:13,,1323854453,7/15/2014 21:38:46,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],"associated with misuse of analgesics, cluster HEADACHE,",n/a,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 21:55:16,,1323859846,7/15/2014 21:53:54,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232581,7/15/2014 22:06:21,,1323864931,7/15/2014 22:06:09,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[TREATS],[TREATS],"HEADACHE,",NONE,124,111,131,132,-1,RO-has_definitional_manifestation,904891-FS1,"In the international classification, the primary headache syndromes include migraine with and without an aura, TENSION TYPE HEADACHE headache associated with misuse of analgesics, cluster HEADACHE, and a number of rare forms of headache with no structural lesion.",HEADACHE,TENSION TYPE HEADACHE
503232582,7/15/2014 14:41:14,,1323602321,7/15/2014 14:41:01,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],in,na,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 14:49:06,,1323605466,7/15/2014 14:48:58,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],morphometric,N/A,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 14:49:56,,1323605793,7/15/2014 14:49:05,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",positive dendritic cells in,na,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 14:59:05,,1323609276,7/15/2014 14:58:33,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],normal human,N/A,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 15:24:32,,1323622563,7/15/2014 15:23:59,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],in the epidermis,N/A,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 15:40:23,,1323634100,7/15/2014 15:39:43,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in,N/A,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 15:44:06,,1323636922,7/15/2014 15:43:02,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[LOCATION],[LOCATION],in,N/A,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 16:23:45,,1323669929,7/15/2014 16:22:40,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],in the epidermis was investigated in,N/A,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 17:10:44,,1323721961,7/15/2014 17:10:06,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],in,N/A,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 18:27:16,,1323772000,7/15/2014 18:27:08,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[IS_A],[IS_A],INFLAMMATORY,n/a,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 19:50:48,,1323810656,7/15/2014 19:49:26,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],cells in the epidermis,N/A,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 20:37:56,,1323829635,7/15/2014 20:37:36,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],in the epidermis,N/A,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 21:44:30,,1323856164,7/15/2014 21:44:11,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],cases INFLAMMATORY DERMATOSES,n/a,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 22:01:20,,1323862689,7/15/2014 22:00:52,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],and in 14 cases of normal human SKIN,n/a,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232582,7/15/2014 22:07:25,,1323865397,7/15/2014 22:06:22,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[MANIFESTATION],[MANIFESTATION],morphometric,NONE,156,100,159,123,1,RO-disease_has_primary_anatomic_site,902112-FS1,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
503232583,7/15/2014 14:54:13,,1323607421,7/15/2014 14:53:11,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[LOCATION],[LOCATION],patches and,na,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 14:54:33,,1323607545,7/15/2014 14:53:52,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],contrast between VITILIGO patches and normal SKIN.,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 15:35:58,,1323630772,7/15/2014 15:35:36,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],skin,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 16:27:35,,1323674516,7/15/2014 16:26:03,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],(most appropriate for skin,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 17:19:46,,1323727121,7/15/2014 17:19:31,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],and,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 18:18:18,,1323768497,7/15/2014 18:17:58,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[LOCATION],[LOCATION],contrast between VITILIGO patches and normal SKIN.,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 18:19:52,,1323769086,7/15/2014 18:18:40,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[LOCATION],[LOCATION],contrast between VITILIGO patches and normal SKIN.,n/a,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 19:17:37,,1323797084,7/15/2014 19:15:34,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,There is a contrast between the two.,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 20:46:17,,1323833024,7/15/2014 20:45:41,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],contrast between VITILIGO patches and normal SKIN.,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 22:26:32,,1323874063,7/15/2014 22:23:44,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[LOCATION],[LOCATION],between,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 22:38:17,,1323880174,7/15/2014 22:37:50,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],contrast between VITILIGO patches and normal SKIN.,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 22:50:11,,1323885611,7/15/2014 22:48:42,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[PART_OF],[PART_OF],VITILIGO patches and normal SKIN.,Part of,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/15/2014 23:11:43,,1323897594,7/15/2014 23:09:34,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[OTHER],[OTHER],artificial tanning preparation containing dihydroxyacetone (DHA) contrast between VITILIGO patches and normal SKIN.,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/16/2014 00:00:21,,1323923314,7/15/2014 23:59:38,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],enhancement of contrast between,n/a,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232583,7/16/2014 00:17:58,,1323935166,7/16/2014 00:16:29,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[PREVENTS],[PREVENTS],prevent burning prevent tanning,N/A,562,534,565,542,1,RO-disease_has_primary_anatomic_site,902476-FS1,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
503232584,7/15/2014 14:45:05,,1323603868,7/15/2014 14:44:42,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],in surgically resected,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 14:53:05,,1323606950,7/15/2014 14:52:32,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],investigate the presence,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 15:02:31,,1323610872,7/15/2014 15:02:12,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[LOCATION],[LOCATION],5 PROSTATIC CARCINOMAS in PROSTATES,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 15:21:32,,1323620543,7/15/2014 15:21:12,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],in surgically resected,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 15:23:54,,1323622162,7/15/2014 15:23:38,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],in surgically resected,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 15:37:04,,1323631609,7/15/2014 15:36:51,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],in surgically resected,N/a,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 15:43:52,,1323636733,7/15/2014 15:43:34,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],in,n/a,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 15:49:06,,1323640571,7/15/2014 15:48:33,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[LOCATION],[LOCATION],in,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 16:00:02,,1323648948,7/15/2014 15:59:11,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],presence,asd,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 16:17:43,,1323663448,7/15/2014 16:17:11,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],in surgically resected,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 16:36:34,,1323685484,7/15/2014 16:35:43,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],in surgically resected,na,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 16:49:28,,1323700245,7/15/2014 16:49:13,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 16:53:07,,1323704160,7/15/2014 16:52:36,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[LOCATION],[LOCATION],in,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 17:13:23,,1323723834,7/15/2014 17:13:06,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],in,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232584,7/15/2014 17:27:51,,1323732012,7/15/2014 17:26:51,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",investigate presence,N/A,124,80,132,100,1,RO-disease_has_primary_anatomic_site,902355-FS1,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
503232585,7/15/2014 14:45:51,,1323604147,7/15/2014 14:45:07,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and of,na,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 14:52:32,,1323606671,7/15/2014 14:52:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],with labetalol.,N/A,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 14:55:04,,1323607719,7/15/2014 14:54:39,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],Treatment,N/A,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 14:57:22,,1323608640,7/15/2014 14:56:55,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],Treatment of and,N/A,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 14:57:47,,1323608738,7/15/2014 14:57:10,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,No relationship between the two conditions in this case,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 15:26:25,,1323623839,7/15/2014 15:26:04,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Two unrelated conditions.,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 15:36:46,,1323631376,7/15/2014 15:36:11,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[NONE],[NONE],N/A,"They are both being treated with the same thing, but are not related to each other.",81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 15:56:36,,1323646287,7/15/2014 15:56:04,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],Brown,asd,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 16:37:21,,1323686349,7/15/2014 16:36:51,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Treatment of PHAEOCHROMOCYTOMA and CLONIDINE WITHDRAWAL HYPERTENSION,n/a,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 17:05:15,,1323717331,7/15/2014 17:03:48,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[NONE],[NONE],N/A,"Both of these are conditions treated by the same drug, but there is no obvious connection between them.",81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 17:15:18,,1323724916,7/15/2014 17:15:05,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 17:16:05,,1323725282,7/15/2014 17:15:43,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION,n/a,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 17:40:01,,1323743164,7/15/2014 17:38:24,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],Treatment,N/A,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 17:54:07,,1323756796,7/15/2014 17:53:12,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION,N/A,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232585,7/15/2014 18:19:02,,1323768789,7/15/2014 18:18:43,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[OTHER],[OTHER],Treatment of PHAEOCHROMOCYTOMA and CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.,N/A,81,56,113,73,-1,RO-disease_may_have_finding,902599-FS1,"Agabiti Rosei E, Brown JJ, Lever AF et al. Treatment of PHAEOCHROMOCYTOMA and of CLONIDINE WITHDRAWAL HYPERTENSION with labetalol.",CLONIDINE WITHDRAWAL HYPERTENSION,PHAEOCHROMOCYTOMA
503232586,7/15/2014 14:47:35,,1323604919,7/15/2014 14:47:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",indistinguishable from,N/A,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 14:50:20,,1323605932,7/15/2014 14:49:45,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],may be,N/A,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 15:03:09,,1323611192,7/15/2014 15:02:32,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],indistinguishable from,N/A,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 15:05:49,,1323612373,7/15/2014 15:05:27,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],PAIN may be indistinguishable from ANGINA PECTORIS,Similar but different conditions,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 15:21:58,,1323620812,7/15/2014 15:21:36,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],indistinguishable from,N/A,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 15:26:08,,1323623633,7/15/2014 15:25:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,"There is no link between the two words. Plus, we don't know which kind of pain we are talking about.",5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 15:31:58,,1323627841,7/15/2014 15:31:19,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],indistinguishable from,n/a,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 15:38:55,,1323633020,7/15/2014 15:38:22,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],may be indistinguishable from,[DIAGNOSE_BY_TEST_OR_DRUG],5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 15:45:17,,1323637875,7/15/2014 15:44:07,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[MANIFESTATION],[MANIFESTATION],indistinguishable,N/A,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 15:57:52,,1323647287,7/15/2014 15:57:33,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],indistinguishable,asd,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 16:39:42,,1323689342,7/15/2014 16:39:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may be indistinguishable,N/A,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 16:46:50,,1323697381,7/15/2014 16:46:02,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[MANIFESTATION],[MANIFESTATION],may be indistinguishable from,na,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 17:12:42,,1323723437,7/15/2014 17:12:02,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],indistinguishable,N/A,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 17:30:06,,1323733977,7/15/2014 17:29:33,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],may,n/a,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232586,7/15/2014 18:10:42,,1323765984,7/15/2014 18:10:00,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],PAIN may be indistinguishable from ANGINA PECTORIS,N/A,5,40,8,55,-1,RO-has_definitional_manifestation,904812-FS1,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
503232587,7/15/2014 15:05:46,,1323612354,7/15/2014 15:05:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlation,Na,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 15:22:34,,1323621281,7/15/2014 15:22:03,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],there is a strong correlation between,N/A,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 15:37:28,,1323631887,7/15/2014 15:37:05,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],ductal carcinoma IN SITU (DCIS) where,N/a,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 15:40:08,,1323633901,7/15/2014 15:39:14,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],strong correlation between,n\a,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 16:04:23,,1323652464,7/15/2014 16:03:31,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",a strong correlation between,N/A,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 16:55:11,,1323706360,7/15/2014 16:54:29,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[NONE],[NONE],na,In Situ is irrelevant and not a medical term.,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 17:33:00,,1323736579,7/15/2014 17:32:37,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",common conditions,n/a,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 18:26:23,,1323771605,7/15/2014 18:26:07,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],additional,n/a,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 18:36:26,,1323775396,7/15/2014 18:35:16,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.,n/a,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 19:15:31,,1323795871,7/15/2014 19:13:53,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.,N/A,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 19:47:31,,1323809671,7/15/2014 19:45:58,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",common conditions strong correlation,N/A,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 20:52:48,,1323835498,7/15/2014 20:51:55,instagc,1.0,13763729,USA,"","",75.182.89.225,[MANIFESTATION],[MANIFESTATION],strong correlation between,N/A,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 22:04:57,,1323864251,7/15/2014 22:04:48,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[SYMPTOM],[SYMPTOM],SITU (DCIS),NONE,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 22:33:31,,1323877576,7/15/2014 22:32:35,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],IN SITU (DCIS) MICROCALCIFICATION CLUSTERS,N/A,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232587,7/15/2014 22:53:12,,1323887280,7/15/2014 22:52:07,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],IN SITU (DCIS) where been shown strong correlation between MICROCALCIFICATION CLUSTERS,Associated With,284,202,310,215,1,RO-disease_may_have_finding,902514-FS1,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
503232588,7/15/2014 14:52:42,,1323606766,7/15/2014 14:51:45,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],DRUG EFFICACY,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 15:18:37,,1323618655,7/15/2014 15:17:39,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],of this procedure,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 15:26:31,,1323623921,7/15/2014 15:26:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],exercise testing is useful for detection of arrhythmias and assessment of,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 15:33:02,,1323628653,7/15/2014 15:32:36,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],with,n\a,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 15:49:59,,1323641297,7/15/2014 15:49:08,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[CONTRAINDICATES],[CONTRAINDICATES],few reports have documented the safety of this procedure,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 16:45:24,,1323695710,7/15/2014 16:44:27,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],procedure,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 18:14:15,,1323767060,7/15/2014 18:11:37,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[NONE],[NONE],n/a,They are talking about the usefulness of testing on two different things,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 18:23:07,,1323770385,7/15/2014 18:22:23,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[OTHER],[OTHER],few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 20:00:23,,1323814046,7/15/2014 19:59:45,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],of this procedure in patients,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 20:45:40,,1323832811,7/15/2014 20:44:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[PREVENTS],[PREVENTS],this procedure in patients,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 22:00:04,,1323862113,7/15/2014 21:59:55,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],arrhythmias,NONE,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 22:05:34,,1323864515,7/15/2014 22:04:51,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[PART_OF],[PART_OF],in patients with,n/a,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 22:41:18,,1323881557,7/15/2014 22:39:56,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],assessment of ANTIARRHYTHMIC DRUG EFFICACY patients with ARRHYTHMIAS.,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 22:56:00,,1323888583,7/15/2014 22:54:13,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CONTRAINDICATES],[CONTRAINDICATES],ANTIARRHYTHMIC DRUG EFFICACY few reports have documented safety procedure in ARRHYTHMIAS.,Contraindicates,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232588,7/15/2014 23:18:18,,1323901100,7/15/2014 23:17:19,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[OTHER],[OTHER],detection arrhythmias assessment ANTIARRHYTHMIC DRUG EFFICACY patients with malignant ventricular ARRHYTHMIAS.,N/A,213,88,223,116,1,RO-may_prevent,907090-FS1,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
503232589,7/15/2014 14:46:01,,1323604193,7/15/2014 14:45:40,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],anemia,N/A,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 14:53:09,,1323606965,7/15/2014 14:52:48,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],for,na,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 15:05:33,,1323612277,7/15/2014 15:05:20,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],THERAPY,Na,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 15:31:01,,1323627219,7/15/2014 15:30:30,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],after THERAPY for,N/a,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 15:44:14,,1323637053,7/15/2014 15:43:55,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],for,N/A,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 15:47:43,,1323639619,7/15/2014 15:47:15,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],THERAPY,n\a,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 15:48:37,,1323640259,7/15/2014 15:48:24,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],THERAPY for,n/a,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 16:34:12,,1323682621,7/15/2014 16:33:29,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],for,na,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 16:45:48,,1323696273,7/15/2014 16:45:25,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],THERAPY for,n/a,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 17:09:12,,1323720844,7/15/2014 17:08:32,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],FLUDARABINE THERAPY for,treated by,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 17:21:39,,1323728104,7/15/2014 17:20:29,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[NONE],[NONE],N/A,No related terms are to be found.,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 17:26:50,,1323731249,7/15/2014 17:26:27,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[TREATS],[TREATS],THERAPY,n/a,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 18:03:06,,1323762881,7/15/2014 18:02:43,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA,N/A,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 18:26:02,,1323771464,7/15/2014 18:25:49,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],for,N/A,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232589,7/15/2014 18:30:11,,1323773241,7/15/2014 18:29:21,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[TREATS],[TREATS],FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA,n/a,86,62,113,81,1,RO-may_treat,907492-FS1,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
503232590,7/15/2014 15:19:43,,1323619339,7/15/2014 15:19:11,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],Prevention of is demonstrable at FISH OIL intakes,N/A,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 15:20:22,,1323619732,7/15/2014 15:19:54,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[PREVENTS],[PREVENTS],Prevention of is demonstrable at,N/A,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 15:35:54,,1323630700,7/15/2014 15:35:26,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",is demonstrable at,[MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG],14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 15:36:34,,1323631248,7/15/2014 15:36:11,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PREVENTS],[PREVENTS],demonstrable at fish FISH OIL intakes,N/a,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 15:41:48,,1323635049,7/15/2014 15:41:03,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[PREVENTS],[PREVENTS],Prevention of is demonstrable at,N/A,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 16:57:58,,1323709685,7/15/2014 16:55:13,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],CARDIAC ARRHYTHMIAS or FISH,na,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 18:26:31,,1323771645,7/15/2014 18:26:24,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],CARDIAC,n/a,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 18:26:43,,1323771774,7/15/2014 18:24:26,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[TREATS],[TREATS],Prevention of CARDIAC ARRHYTHMIAS is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure,n/a,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 18:44:06,,1323779117,7/15/2014 18:43:20,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PREVENTS],[PREVENTS],is demonstrable,N/A,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 21:44:11,,1323856041,7/15/2014 21:43:40,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],demonstrable at fish intakes,n/a,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 21:44:18,,1323856129,7/15/2014 21:41:28,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[NONE] [PREVENTS],"[PREVENTS]
[NONE]",have little or no effect,the sentence is saying fish oils don't have an effect on a sympton of the condition,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 22:06:08,,1323864775,7/15/2014 22:05:38,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ARRHYTHMIAS,NONE,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 22:07:28,,1323865422,7/15/2014 22:06:59,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[PREVENTS],[PREVENTS],is demonstrable at fish or FISH OIL intakes,n/a,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 22:31:50,,1323876620,7/15/2014 22:30:44,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[NONE],[NONE],N/A,There is no relation between the words.,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232590,7/15/2014 22:39:56,,1323881029,7/15/2014 22:39:19,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",CARDIAC ARRHYTHMIAS is demonstrable FISH OIL intakes lipids.,N/A,14,78,32,86,1,RO-may_prevent,907011-FS1,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
503232591,7/15/2014 14:47:00,,1323604655,7/15/2014 14:46:20,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[LOCATION],[LOCATION],activity of the,na,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 14:50:58,,1323606132,7/15/2014 14:50:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared,N/A,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 15:00:46,,1323609911,7/15/2014 15:00:14,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",was studied,N/A,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 15:04:01,,1323611610,7/15/2014 15:03:10,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",was studied of one or both knees,N/A,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 15:24:07,,1323622322,7/15/2014 15:23:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was studied in patients with,N/A,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 15:27:40,,1323624694,7/15/2014 15:27:02,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],studied one or both knees,N/A,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 15:53:49,,1323644196,7/15/2014 15:53:29,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],activity of,n/a,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 16:49:48,,1323700616,7/15/2014 16:49:30,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],one or both,N/A,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 17:13:05,,1323723661,7/15/2014 17:12:41,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[LOCATION],[LOCATION],KNEE JOINTS one or both knees,na,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 17:56:34,,1323759378,7/15/2014 17:56:04,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],KNEE JOINTS with CLINICAL ARTHRITIS,N/A,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 18:04:23,,1323763593,7/15/2014 18:04:02,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],99mTechnetium pertechnetate,n/a,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 18:22:21,,1323769940,7/15/2014 18:21:48,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[LOCATION],[LOCATION],CLINICAL ARTHRITIS of one or both knees,N/A,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 18:31:05,,1323773530,7/15/2014 18:30:30,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],the activity of the JOINTS in patients with CLINICAL ARTHRITIS of one both knees,N/A,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 18:32:54,,1323774081,7/15/2014 18:32:12,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[LOCATION],[LOCATION],activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS,n/a,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232591,7/15/2014 18:55:33,,1323785168,7/15/2014 18:55:28,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,109,150,119,168,1,RO-disease_has_primary_anatomic_site,902085-FS1,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
503232592,7/15/2014 14:45:27,,1323604007,7/15/2014 14:45:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],SUGAR,N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 14:57:08,,1323608554,7/15/2014 14:56:36,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[PART_OF],[PART_OF],50% of the total CARBOHYDRATE are (up to three SUGAR RESIDUES),N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 14:59:35,,1323609439,7/15/2014 14:58:49,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],composed,N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 15:00:31,,1323609835,7/15/2014 14:59:45,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],which make up,N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 15:24:14,,1323622386,7/15/2014 15:23:33,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],(up to three,N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 15:48:33,,1323640193,7/15/2014 15:47:38,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],make up,N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 16:50:04,,1323700961,7/15/2014 16:49:49,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],(up to three,N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 17:14:25,,1323724396,7/15/2014 17:13:23,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[PART_OF],[PART_OF],"sugars, make up CARBOHYDRATE (up to three SUGAR RESIDUES)",N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 17:20:27,,1323727543,7/15/2014 17:20:04,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],(up to,N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 18:28:15,,1323772494,7/15/2014 18:28:08,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],are,n/a,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 18:35:15,,1323774916,7/15/2014 18:32:55,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[PART_OF],[PART_OF],"The glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains",n/a,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 18:57:48,,1323786364,7/15/2014 18:57:43,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 20:13:25,,1323819740,7/15/2014 20:11:38,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[IS_A],[IS_A],(up to three,N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 21:32:49,,1323852441,7/15/2014 21:32:01,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[PART_OF],[PART_OF],CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains,N/A,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232592,7/15/2014 22:03:38,,1323863667,7/15/2014 22:02:57,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[LOCATION],[LOCATION],residues.,NONE,92,56,105,68,1,RO-has_ingredient,905595-FS1,"The O glycosidic sugars, which make up 50% of the total CARBOHYDRATE are short (up to three SUGAR RESIDUES) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",SUGAR RESIDUES,CARBOHYDRATE
503232593,7/15/2014 14:49:47,,1323605749,7/15/2014 14:49:37,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],percentage,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 14:52:52,,1323606862,7/15/2014 14:52:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],who relapsed into,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 15:27:01,,1323624245,7/15/2014 15:26:08,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],relapsed into,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 15:33:15,,1323628827,7/15/2014 15:32:30,elite,1,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[SIDE_EFFECT]",who relapsed into,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [SIDE_EFFECT],115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 15:49:12,,1323640682,7/15/2014 15:48:45,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relapsed into,N/a,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 16:41:56,,1323691830,7/15/2014 16:41:30,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 16:42:34,,1323692543,7/15/2014 16:42:13,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],relapsed,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 16:49:20,,1323700059,7/15/2014 16:48:31,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],who relapsed into,na,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 17:21:23,,1323728012,7/15/2014 17:21:05,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],relapsed into,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 17:24:01,,1323729284,7/15/2014 17:22:56,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",relapsed,n/a,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 17:42:41,,1323745568,7/15/2014 17:41:37,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],we did not find increase,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 18:27:30,,1323772133,7/15/2014 18:25:58,prodege,1,9378607,GBR,H9,London,90.201.89.10,[IS_A],[IS_A],patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 21:40:12,,1323854756,7/15/2014 21:38:23,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[CAUSES],[CAUSES],who relapsed into,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 21:53:52,,1323859262,7/15/2014 21:52:50,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],who relapsed into,n/a,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232593,7/15/2014 22:26:54,,1323874310,7/15/2014 22:26:06,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],GRAVES' DISEASE relapsed into GRAVES' THYROTOXICOSIS,N/A,115,149,129,171,-1,RO-cause_of,900460-FS1,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
503232594,7/15/2014 14:54:35,,1323607548,7/15/2014 14:54:14,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[IS_A],[IS_A],from the group,na,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 15:07:55,,1323613274,7/15/2014 15:07:08,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],ATYPIA ATYPICAL,N/A,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 15:15:03,,1323616808,7/15/2014 15:14:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Two unrelated conditions,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 15:19:09,,1323618977,7/15/2014 15:18:25,prodege,1,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],hyperplasia without ATYPIA,N/A,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 15:21:37,,1323620562,7/15/2014 15:20:53,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],group of hyperplasia without ATYPIA and ATYPICAL HYPERPLASIA,N/A,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 15:23:44,,1323622068,7/15/2014 15:23:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],from the group of adenocarcinoma and,N/A,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 15:34:37,,1323629788,7/15/2014 15:34:17,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],without,N/a,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 15:43:54,,1323636750,7/15/2014 15:42:56,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[OTHER],[OTHER],differentiation of the group without from the group,n\a,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 15:51:22,,1323642379,7/15/2014 15:50:00,prodege,1,27979711,CAN,ON,Stouffville,99.247.121.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],possible differentiation from the group,N/A,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 16:44:17,,1323694319,7/15/2014 16:43:55,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],from,N/A,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 16:45:32,,1323695868,7/15/2014 16:44:25,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,no relation between the two,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 16:59:53,,1323712090,7/15/2014 16:58:41,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[OTHER],[OTHER],differentiation of from,N/A,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 17:15:23,,1323724948,7/15/2014 17:14:58,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA,n/a,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 17:16:49,,1323725676,7/15/2014 17:16:31,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[IS_A],[IS_A],from the group,N/A,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232594,7/15/2014 17:48:57,,1323751569,7/15/2014 17:48:46,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],group,N/A,245,289,250,309,1,RO-disease_has_finding,901792-FS1,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without ATYPIA from the group of adenocarcinoma and ATYPICAL HYPERPLASIA",ATYPIA,ATYPICAL HYPERPLASIA
503232595,7/15/2014 14:46:53,,1323604619,7/15/2014 14:46:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],seven forms of,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 14:48:57,,1323605438,7/15/2014 14:48:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pulmonary,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 14:58:32,,1323609052,7/15/2014 14:57:58,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],seven forms of pulmonary infiltrates,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 14:58:38,,1323609098,7/15/2014 14:58:14,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,Two different condition types,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 15:05:37,,1323612305,7/15/2014 15:05:09,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],seven forms of,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 15:27:19,,1323624413,7/15/2014 15:26:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],There are seven forms of pulmonary infiltrates with peripheral eosinophilia,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 15:31:31,,1323627547,7/15/2014 15:30:12,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[OTHER],[OTHER],seven forms of pulmonary infiltrates (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (4) tropical PULMONARY EOSINOPHILIA;,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 15:32:05,,1323627915,7/15/2014 15:31:46,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[OTHER],[OTHER],seven forms of pulmonary infiltrates (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (4) tropical PULMONARY EOSINOPHILIA;,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 15:35:29,,1323630393,7/15/2014 15:35:11,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seven forms of,N/a,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 15:37:08,,1323631662,7/15/2014 15:36:24,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[OTHER],[OTHER],seven forms of,n\a,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 15:37:22,,1323631818,7/15/2014 15:36:55,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[IS_A],[IS_A],eosinophilia,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 15:45:34,,1323638062,7/15/2014 15:44:56,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different types of infiltrates,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 15:45:44,,1323638158,7/15/2014 15:45:09,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pulmonary eosinophilia with asthma,[ASSOCIATED_WITH],141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 16:01:26,,1323650067,7/15/2014 15:59:36,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PART_OF] [OTHER],"[PART_OF]
[OTHER]",There are seven forms of,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 16:19:00,,1323664644,7/15/2014 16:18:39,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],seven forms of,n/a,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232595,7/15/2014 16:48:08,,1323698753,7/15/2014 16:47:45,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PULMONARY EOSINOPHILIA PULMONARY EOSINOPHILIA;,N/A,141,151,187,173,-1,RO-has_definitional_manifestation,904785-FS1,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical PULMONARY EOSINOPHILIA; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,PROLONGED PULMONARY EOSINOPHILIA WITHOUT ASTHMA,PULMONARY EOSINOPHILIA
503232596,7/15/2014 14:46:41,,1323604517,7/15/2014 14:45:53,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],untreated with,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 14:49:50,,1323605783,7/15/2014 14:49:13,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],previously untreated,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 14:50:07,,1323605853,7/15/2014 14:49:58,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],levodopa,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 14:52:47,,1323606824,7/15/2014 14:52:21,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],previously untreated,na,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 15:22:52,,1323621458,7/15/2014 15:21:46,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],effects,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 15:22:55,,1323621474,7/15/2014 15:21:59,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[SIDE_EFFECT],[SIDE_EFFECT],in previously untreated patients with,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 15:33:52,,1323629290,7/15/2014 15:33:35,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],in previously untreated patients,N/a,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 15:36:01,,1323630816,7/15/2014 15:35:17,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],neuroprotective effects compared,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 15:43:01,,1323636005,7/15/2014 15:41:28,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],evaluated effects,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 15:46:19,,1323638625,7/15/2014 15:45:25,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[MANIFESTATION],[MANIFESTATION],in previously untreated patients with,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 16:17:34,,1323663332,7/15/2014 16:16:53,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[TREATS],[TREATS],STUDY SELECTION,asd,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 16:57:32,,1323709206,7/15/2014 16:57:12,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],previously untreated,n/a,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 17:22:05,,1323728309,7/15/2014 17:21:40,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],untreated patients,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 17:25:47,,1323730501,7/15/2014 17:24:26,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluated they compared,N/A,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232596,7/15/2014 17:38:22,,1323741564,7/15/2014 17:38:02,clixsense,1,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,Na,278,213,279,239,1,RO-may_treat,907810-FS1,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
503232597,7/15/2014 14:51:55,,1323606489,7/15/2014 14:51:23,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",predisposition,na,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 14:52:09,,1323606561,7/15/2014 14:51:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],is determined,N/A,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 15:32:28,,1323628214,7/15/2014 15:31:41,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",susceptibility because,[SYMPTOM] [ASSOCIATED_WITH],103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 15:39:13,,1323633231,7/15/2014 15:38:26,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[MANIFESTATION],[MANIFESTATION],factors,n\a,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 15:46:04,,1323638415,7/15/2014 15:45:37,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[PART_OF],[PART_OF],susceptibility because,N/A,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 16:48:31,,1323699199,7/15/2014 16:48:09,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],SEIZURE SEIZURE,N/A,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 17:30:33,,1323734334,7/15/2014 17:28:48,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],factors present from birth.,N/A,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 17:49:07,,1323751705,7/15/2014 17:48:58,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURE SEIZURE,N/A,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 18:02:13,,1323762581,7/15/2014 18:01:50,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[PART_OF],[PART_OF],SEIZURE,both have the same root name,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 18:26:15,,1323771545,7/15/2014 18:24:30,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[IS_A],[IS_A],NEONATAL SEIZURE SEIZURE,N/A,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 18:28:46,,1323772714,7/15/2014 18:28:40,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],in,n/a,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 18:50:45,,1323782574,7/15/2014 18:50:30,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A],[IS_A],SEIZURE SEIZURE,N/A,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 21:46:10,,1323856744,7/15/2014 21:44:49,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[IS_A],[IS_A],NEONATAL SEIZURE susceptibility because SEIZURE predisposition,N/A,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 22:17:02,,1323869736,7/15/2014 22:16:20,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],susceptibility,n/a,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232597,7/15/2014 23:06:22,,1323894475,7/15/2014 23:05:23,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],NEONATAL SEIZURE susceptibility because SEIZURE predisposition,Is A,103,94,109,110,-1,RO-has_definitional_manifestation,904787-FS1,The genetically epilepsy prone rat (GEPR) provides a valuable model to study the mechanism of NEONATAL SEIZURE susceptibility because SEIZURE predisposition in GEPRs is determined by factors present from birth.,SEIZURE,NEONATAL SEIZURE
503232598,7/15/2014 14:45:47,,1323604128,7/15/2014 14:45:16,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],cells,N/A,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 14:46:19,,1323604389,7/15/2014 14:45:53,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cells of,na,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 15:03:06,,1323611193,7/15/2014 15:02:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],cells,Na,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 15:43:54,,1323636742,7/15/2014 15:43:33,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[LOCATION],[LOCATION],cells,N/A,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 16:33:25,,1323681785,7/15/2014 16:31:39,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",ASCITES cells of HEPATOMA,N/A,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 16:40:06,,1323689750,7/15/2014 16:39:42,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],cells of,ha,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 16:56:32,,1323707996,7/15/2014 16:56:12,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],cells of,n/a,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 17:09:32,,1323721087,7/15/2014 17:08:32,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[PART_OF],[PART_OF],ASCITES cells of HEPATOMA,N/A,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 17:22:55,,1323728682,7/15/2014 17:22:31,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[LOCATION],[LOCATION],cells rat liver,n/a,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 18:37:33,,1323775851,7/15/2014 18:36:53,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],ASCITES cells of HEPATOMA,N/A,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 20:19:13,,1323822008,7/15/2014 20:18:28,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],cells of,N/A,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 20:54:11,,1323835955,7/15/2014 20:53:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],activities of in various,N/A,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 22:02:02,,1323863036,7/15/2014 22:01:40,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[CAUSES],[CAUSES],HEPATOMA,NONE,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 22:08:26,,1323865967,7/15/2014 22:07:48,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],cells of,n/a,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232598,7/15/2014 22:35:24,,1323878738,7/15/2014 22:34:43,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],various rat ASCITES cells of HEPATOMA,N/A,58,75,64,83,-1,RO-disease_may_have_finding,902643-FS1,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
503232599,7/15/2014 14:47:02,,1323604671,7/15/2014 14:46:51,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SYMPTOM],[SYMPTOM],of,N/A,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 14:54:37,,1323607550,7/15/2014 14:54:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],objective of study was to assess,N/A,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 15:06:42,,1323612820,7/15/2014 15:06:22,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],HYPERTENSION or BLOOD PRESSURE ELEVATION,N/A,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 15:24:27,,1323622506,7/15/2014 15:24:15,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/a,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 15:24:46,,1323622748,7/15/2014 15:24:14,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],or,N/A,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 15:30:20,,1323626722,7/15/2014 15:29:51,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assess the impact of,[DIAGNOSE_BY_TEST_OR_DRUG],92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 15:44:56,,1323637589,7/15/2014 15:43:52,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],or,n/a,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 16:23:09,,1323669226,7/15/2014 16:22:06,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[OTHER],[OTHER],or,a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 17:06:35,,1323718589,7/15/2014 17:06:10,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTENSION or BLOOD PRESSURE ELEVATION,na,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 17:32:23,,1323736021,7/15/2014 17:31:19,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[OTHER],[OTHER],the,n/a,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 17:36:42,,1323739979,7/15/2014 17:36:05,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],present study diagnostic performance,N/A,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 18:02:59,,1323762837,7/15/2014 18:02:10,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[IS_A],[IS_A],HYPERTENSION or BLOOD PRESSURE ELEVATION,N/A,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 18:26:38,,1323771717,7/15/2014 18:26:32,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SIDE_EFFECT],[SIDE_EFFECT],present,n/a,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 18:39:54,,1323777055,7/15/2014 18:39:20,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],or,N/A,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232599,7/15/2014 18:51:22,,1323782940,7/15/2014 18:51:00,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],history of HYPERTENSION or BLOOD PRESSURE ELEVATION,N/A,92,76,115,88,-1,RO-has_definitional_manifestation,904546-FS1,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
503232600,7/15/2014 14:46:20,,1323604397,7/15/2014 14:46:13,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],department,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 14:47:07,,1323604751,7/15/2014 14:46:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed the diagnosis of,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 14:54:59,,1323607681,7/15/2014 14:54:36,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed,na,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 14:55:58,,1323608043,7/15/2014 14:55:25,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TEST confirmed the diagnosis,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 15:00:04,,1323609622,7/15/2014 14:59:50,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],EDROPHONIUM (TENSILON) TEST confirmed diagnosis of MYASTHENIA GRAVIS,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 15:21:44,,1323620679,7/15/2014 15:21:26,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],EDROPHONIUM TEST,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 15:25:07,,1323622909,7/15/2014 15:24:41,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed the diagnosis of,[DIAGNOSE_BY_TEST_OR_DRUG],93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 15:28:09,,1323625059,7/15/2014 15:27:53,instagc,1.0,18960682,GBR,"","",86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed the diagnosis of,N/a,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 15:33:58,,1323629352,7/15/2014 15:33:42,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 16:42:22,,1323692303,7/15/2014 16:42:00,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 17:50:37,,1323753189,7/15/2014 17:50:18,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EDROPHONIUM (TENSILON) TEST,n/a,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 18:29:18,,1323772935,7/15/2014 18:29:13,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],EDROPHONIUM,n/a,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 18:43:19,,1323778722,7/15/2014 18:42:53,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TEST confirmed the diagnosis,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 19:20:31,,1323798442,7/15/2014 19:20:09,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],EDROPHONIUM (TENSILON) TEST confirmed the diagnosis of MYASTHENIA GRAVIS,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232600,7/15/2014 20:04:34,,1323816130,7/15/2014 20:02:09,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed the diagnosis of,N/A,93,10,109,37,1,RO-may_diagnose,906604-FS1,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
503232601,7/15/2014 14:53:51,,1323607244,7/15/2014 14:52:43,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],DEPENDENCE,N/A,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 14:56:43,,1323608364,7/15/2014 14:56:12,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],expectations that,na,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 14:57:26,,1323608656,7/15/2014 14:56:43,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related to,N/A,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 15:01:09,,1323610100,7/15/2014 15:00:27,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],NICOTINE DEPENDENCE NICOTINE use would ameliorate such affect.,N/A,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 15:46:15,,1323638542,7/15/2014 15:45:34,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],related to,n/a,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 16:48:36,,1323699282,7/15/2014 16:47:58,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[CAUSES],[CAUSES],NICOTINE DEPENDENCE,N/A,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 16:56:42,,1323708193,7/15/2014 16:55:42,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],use,na,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 17:11:30,,1323722479,7/15/2014 17:11:00,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],ameliorate,N/A,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 17:28:10,,1323732296,7/15/2014 17:26:51,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],DEPENDENCE,n/a,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 18:27:23,,1323772051,7/15/2014 18:27:16,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],should,n/a,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 20:02:08,,1323814877,7/15/2014 20:00:24,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],should be related to,N/A,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 20:42:57,,1323831529,7/15/2014 20:42:09,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],use would ameliorate,N/A,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 21:41:55,,1323855285,7/15/2014 21:41:22,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],individual's tendency to experience negative use would ameliorate such affect.,n/a,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 22:07:36,,1323865485,7/15/2014 22:07:26,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[MANIFESTATION],[MANIFESTATION],tendency,NONE,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232601,7/15/2014 22:29:19,,1323875506,7/15/2014 22:28:21,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related,N/A,33,33,40,52,1,RO-has_causative_agent,903738-FS1,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
503232602,7/15/2014 14:51:49,,1323606457,7/15/2014 14:50:53,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],without are at low risk for,N/A,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 15:02:34,,1323610900,7/15/2014 15:02:20,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],low risk,Na,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 15:20:52,,1323620100,7/15/2014 15:20:14,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],without POSTMENOPAUSAL BLEEDING are at low risk,N/A,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 15:23:09,,1323621641,7/15/2014 15:22:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],are at low risk for having,N/A,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 15:27:58,,1323624906,7/15/2014 15:27:18,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",are at low risk for having,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 15:33:33,,1323629046,7/15/2014 15:33:19,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CONTRAINDICATES],[CONTRAINDICATES],are at low risk for having,N/a,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 15:55:09,,1323645244,7/15/2014 15:54:40,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],having,n/a,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 18:25:47,,1323771415,7/15/2014 18:25:31,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],bleeding,n/a,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 18:51:47,,1323783176,7/15/2014 18:51:23,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,N/A,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 18:55:41,,1323785242,7/15/2014 18:55:35,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 18:59:45,,1323787742,7/15/2014 18:58:51,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SYMPTOM],[SYMPTOM],without low risk,not applicable,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 20:09:58,,1323818366,7/15/2014 20:06:56,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[MANIFESTATION],[MANIFESTATION],without are at low risk for having,N/A,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 20:50:38,,1323834729,7/15/2014 20:50:12,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],without at low risk,N/A,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 21:45:48,,1323856642,7/15/2014 21:45:29,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],postmenopausal without POSTMENOPAUSAL BLEEDING low risk for having ENDOMETRIAL CANCER,n/a,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232602,7/15/2014 21:58:40,,1323861361,7/15/2014 21:57:32,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],without are at low risk for having,n/a,101,152,123,170,-1,RO-disease_may_have_finding,902927-FS1,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
503232603,7/15/2014 15:00:29,,1323609823,7/15/2014 15:00:04,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",characterized by,na,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 15:45:32,,1323638002,7/15/2014 15:45:03,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[MANIFESTATION],[MANIFESTATION],characterized by,n\a,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 16:37:55,,1323687049,7/15/2014 16:37:30,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM],[SYMPTOM],characterized by,N/A,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 16:39:27,,1323689033,7/15/2014 16:39:14,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],characterized,N/A,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 16:40:13,,1323689946,7/15/2014 16:38:16,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],characterized by,n/a,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 17:15:36,,1323725030,7/15/2014 17:15:20,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],characterized,N/A,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 17:49:14,,1323751855,7/15/2014 17:49:08,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],syndrome,N/A,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 18:20:23,,1323769222,7/15/2014 18:19:52,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA,n/a,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 18:24:29,,1323770898,7/15/2014 18:23:08,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[SYMPTOM],[SYMPTOM],ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA,N/A,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 18:25:58,,1323771436,7/15/2014 18:25:48,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],characterized,n/a,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 20:46:39,,1323833163,7/15/2014 20:46:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],syndrome characterized by,N/A,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 21:50:37,,1323858159,7/15/2014 21:50:18,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is a syndrome characterized by,n/a,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 22:15:36,,1323869074,7/15/2014 22:15:15,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[SYMPTOM],[SYMPTOM],characterized by,n/a,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 22:25:33,,1323873607,7/15/2014 22:24:45,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",ONCOGENIC OSTEOMALACIA characterized by PHOSPHATURIA,N/A,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232603,7/15/2014 22:32:09,,1323876790,7/15/2014 22:31:51,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[SYMPTOM],[SYMPTOM],characterized by,N/A,54,0,65,22,1,RO-disease_has_finding,901839-FS1,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
503232604,7/15/2014 14:58:13,,1323608922,7/15/2014 14:57:49,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],VENTRICULAR TACHYCARDIA DISOPYRAMIDE,All part of same term,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 15:43:20,,1323636243,7/15/2014 15:42:39,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION] [TREATS],"[TREATS]
[MANIFESTATION]",was capable to interrupt the arrhythmias.,[MANIFESTATION] [TREATS],233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 16:06:20,,1323654102,7/15/2014 16:05:59,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],contractions,asd,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 16:43:36,,1323693631,7/15/2014 16:42:42,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],was capable to interrupt the arrhythmias.,na,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 16:48:48,,1323699512,7/15/2014 16:47:20,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],VENTRICULAR TACHYCARDIA DISOPYRAMIDE,They make up the term,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 16:53:24,,1323704498,7/15/2014 16:52:01,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],100% of,n/a,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 17:15:43,,1323725105,7/15/2014 17:15:24,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PART_OF],[PART_OF],VENTRICULAR TACHYCARDIA DISOPYRAMIDE,n/a,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 17:57:47,,1323760544,7/15/2014 17:57:19,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[PART_OF],[PART_OF],VENTRICULAR TACHYCARDIA DISOPYRAMIDE,it is all one medical term,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 18:00:38,,1323761959,7/15/2014 18:00:04,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],VENTRICULAR TACHYCARDIA DISOPYRAMIDE interrupt arrhythmias.,N/A,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 18:05:08,,1323763892,7/15/2014 18:04:24,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",interrupted drug injection;,n/a,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 18:31:37,,1323773718,7/15/2014 18:31:05,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE,N/A,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 18:31:43,,1323773735,7/15/2014 18:31:09,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[PART_OF],[PART_OF],VENTRICULAR TACHYCARDIA DISOPYRAMIDE,N/A,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 18:52:39,,1323783649,7/15/2014 18:51:48,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],VENTRICULAR TACHYCARDIA DISOPYRAMIDE,N/A,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 18:56:13,,1323785554,7/15/2014 18:56:07,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232604,7/15/2014 19:31:24,,1323803210,7/15/2014 19:31:03,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.,N/A,233,257,255,269,1,RO-may_prevent,907380-FS1,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
503232605,7/15/2014 14:40:17,,1323602062,7/15/2014 14:40:03,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],"protection,",na,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 14:47:12,,1323604773,7/15/2014 14:47:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],extent,N/A,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 14:49:12,,1323605505,7/15/2014 14:48:35,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],provided by oral,N/A,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 15:02:10,,1323610700,7/15/2014 15:01:49,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,Two different concepts compared,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 15:11:57,,1323615219,7/15/2014 15:11:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],similar in extent to that provided by,N/A,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 15:13:46,,1323616121,7/15/2014 15:13:28,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],"protection, provided by",N/A,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 15:14:15,,1323616358,7/15/2014 15:13:30,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],"provides significant MOTION SICKNESS protection,",N/A,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 15:45:16,,1323637866,7/15/2014 15:44:54,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],"protection,",N/A,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 15:57:29,,1323646982,7/15/2014 15:57:03,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[PREVENTS],[PREVENTS],scopolamine,asd,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 16:43:22,,1323693418,7/15/2014 16:43:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar,N/A,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 16:55:41,,1323706894,7/15/2014 16:55:19,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PREVENTS],[PREVENTS],"provides significant protection,",n/a,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 17:19:31,,1323726994,7/15/2014 17:19:04,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PREVENTS],[PREVENTS],"protection,",N/A,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 17:25:30,,1323730319,7/15/2014 17:24:47,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar,n/a,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 17:42:04,,1323745023,7/15/2014 17:41:33,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar,N/A,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232605,7/15/2014 18:10:57,,1323766070,7/15/2014 18:10:19,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[NONE],[NONE],N/A,Do not go together in the same concept.,45,116,59,127,1,RO-may_prevent,907382-FS1,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
503232606,7/15/2014 14:38:49,,1323601421,7/15/2014 14:38:12,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],primary,na,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 14:44:41,,1323603643,7/15/2014 14:44:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],are the primary,N/A,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 14:54:00,,1323607296,7/15/2014 14:53:30,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],are the primary,N/A,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 15:05:02,,1323612041,7/15/2014 15:04:42,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INFLUENZA A AND B VIRUSES RESPIRATORY TRACT VIRUSES associated with disease.,N/A,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 15:22:02,,1323620876,7/15/2014 15:21:52,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],are the primary,N/A,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 15:36:54,,1323631479,7/15/2014 15:36:24,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],are the primary,N/A,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 16:22:04,,1323668008,7/15/2014 16:20:56,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[CAUSES],[CAUSES],primary associated with this disease.,respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 16:43:59,,1323693998,7/15/2014 16:42:47,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],primary,n/a,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 16:51:21,,1323702283,7/15/2014 16:51:02,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],are the primary,N/A,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 16:58:19,,1323710035,7/15/2014 16:56:44,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[PART_OF],[PART_OF],are the primary associated with this disease.,na,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 17:15:39,,1323725083,7/15/2014 17:15:20,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[IS_A],[IS_A],are the primary,na,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 18:14:55,,1323767287,7/15/2014 18:14:16,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[IS_A],[IS_A],INFLUENZA A AND B VIRUSES are the primary RESPIRATORY TRACT VIRUSES,n/a,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 18:27:53,,1323772366,7/15/2014 18:27:46,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],virus,n/a,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 18:33:44,,1323774394,7/15/2014 18:33:06,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],are the primary associated with this disease.,N/A,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232606,7/15/2014 18:58:51,,1323787126,7/15/2014 18:58:10,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,not applicable,86,0,110,25,1,RO-has_finding_site,905361-FS1,"INFLUENZA A AND B VIRUSES adenovirus, and respiratory syncytial virus are the primary RESPIRATORY TRACT VIRUSES associated with this disease.",RESPIRATORY TRACT VIRUSES,INFLUENZA A AND B VIRUSES
503232607,7/15/2014 14:50:48,,1323606057,7/15/2014 14:50:38,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],neuropsychological,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 14:56:34,,1323608326,7/15/2014 14:56:13,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[PART_OF],[PART_OF],MILD TO MODERATE INTELLECTUAL DISABILITY is PART OF WAGR SYNDROME,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 15:01:49,,1323610482,7/15/2014 15:01:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],considered PART OF,Na,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 15:15:26,,1323616992,7/15/2014 15:15:05,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],is considered,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 15:23:57,,1323622178,7/15/2014 15:23:45,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],is usually considered PART OF,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 15:23:58,,1323622183,7/15/2014 15:23:31,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],PART OF,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 15:48:16,,1323640027,7/15/2014 15:47:56,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],usually considered PART,N/a,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 16:07:25,,1323654917,7/15/2014 16:06:49,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],INTELLECTUAL DISABILITY,asd,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 16:35:09,,1323683740,7/15/2014 16:34:27,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [MANIFESTATION] [ASSOCIATED_WITH],"[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]",is usually considered PART OF,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 16:40:41,,1323690502,7/15/2014 16:40:24,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],considered,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 16:55:13,,1323706374,7/15/2014 16:54:37,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[SYMPTOM],[SYMPTOM],is PART OF,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 17:07:03,,1323719056,7/15/2014 17:06:36,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[PART_OF],[PART_OF],is usually considered PART OF,na,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 17:28:45,,1323732910,7/15/2014 17:27:52,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[PART_OF],[PART_OF],usually considered PART OF,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 17:39:26,,1323742589,7/15/2014 17:39:03,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],considered PART,Na,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232607,7/15/2014 17:47:24,,1323750073,7/15/2014 17:46:59,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PART_OF],[PART_OF],PART OF,N/A,9,72,48,93,-1,RO-has_manifestation,906332-FS1,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
503232608,7/15/2014 14:47:44,,1323604966,7/15/2014 14:46:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES] [TREATS],"[TREATS]
[CAUSES]",treatment with has to,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 14:48:48,,1323605388,7/15/2014 14:48:39,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],bleeding,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 14:50:53,,1323606098,7/15/2014 14:50:29,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 14:52:01,,1323606521,7/15/2014 14:51:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treatment with,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 15:23:37,,1323621995,7/15/2014 15:23:21,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],treatment with in,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 15:28:38,,1323625365,7/15/2014 15:28:30,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],in,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 16:10:51,,1323657615,7/15/2014 16:10:06,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[TREATS],[TREATS],length,asd,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 16:37:54,,1323687038,7/15/2014 16:37:32,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 16:44:25,,1323694438,7/15/2014 16:44:00,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment,n/a,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 16:45:35,,1323695934,7/15/2014 16:44:35,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[TREATS],[TREATS],treatment,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 17:10:59,,1323722175,7/15/2014 17:09:36,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[TREATS],[TREATS],treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 18:09:58,,1323765773,7/15/2014 18:09:28,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 18:40:14,,1323777158,7/15/2014 18:39:55,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],in,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 18:57:42,,1323786323,7/15/2014 18:57:37,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232608,7/15/2014 20:11:37,,1323819050,7/15/2014 20:10:46,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],treatment with,N/A,77,45,91,73,1,RO-may_treat,908115-FS1,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
503232609,7/15/2014 14:41:00,,1323602263,7/15/2014 14:40:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],examined,na,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 15:08:53,,1323613706,7/15/2014 15:08:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],examined with,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 15:25:41,,1323623364,7/15/2014 15:25:23,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],were examined and,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 15:26:52,,1323624154,7/15/2014 15:26:43,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 15:34:19,,1323629570,7/15/2014 15:33:59,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],LENSES,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 15:46:56,,1323639010,7/15/2014 15:46:39,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[LOCATION],[LOCATION],examined,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 15:54:20,,1323644603,7/15/2014 15:53:50,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different parts,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 16:08:36,,1323655838,7/15/2014 16:07:08,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],were examined with,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 16:37:30,,1323686613,7/15/2014 16:36:14,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 16:47:44,,1323698337,7/15/2014 16:47:30,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],were examined,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 16:53:43,,1323704776,7/15/2014 16:53:13,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[OTHER],[OTHER],and,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 17:47:45,,1323750389,7/15/2014 17:47:37,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],LENSES,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 17:57:07,,1323759956,7/15/2014 17:56:36,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],LENSES examined with CATARACTS,N/A,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 18:36:54,,1323775625,7/15/2014 18:36:27,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[LOCATION],[LOCATION],LENSES were examined and CATARACTS were graded,n/a,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232609,7/15/2014 21:59:37,,1323861843,7/15/2014 21:58:40,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They were in two separate tests.,0,42,5,51,1,RO-has_finding_site,905124-FS1,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
503232610,7/15/2014 14:53:25,,1323607085,7/15/2014 14:52:45,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],established by,N/A,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 15:24:44,,1323622708,7/15/2014 15:24:24,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],injection of,N/A,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 16:45:44,,1323696151,7/15/2014 16:45:25,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],intravenous injection,N/A,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 16:51:34,,1323702503,7/15/2014 16:51:07,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[CAUSES],[CAUSES],established by intravenous injection of ENDOTOXIN,na,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 18:30:04,,1323773186,7/15/2014 18:29:29,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],was established by intravenous injection,N/A,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 18:57:37,,1323786244,7/15/2014 18:57:32,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 19:01:43,,1323789013,7/15/2014 19:01:03,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],injection,not applicable,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 19:20:08,,1323798284,7/15/2014 19:17:58,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[CAUSES],[CAUSES],ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN,N/A,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 19:55:02,,1323812122,7/15/2014 19:54:05,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],was established by intravenous injection,N/A,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 22:03:53,,1323863798,7/15/2014 22:03:39,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[PREVENTS],[PREVENTS],ENDOTOXIN,NONE,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 22:12:38,,1323867833,7/15/2014 22:10:41,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,"One was used to demonstrate the other, but they are not exactly related.",201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 22:28:04,,1323874829,7/15/2014 22:27:19,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],ENDOTOXIC SHOCK was established by ENDOTOXIN,N/A,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 22:59:42,,1323890240,7/15/2014 22:58:48,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SIDE_EFFECT],[SIDE_EFFECT],"ENDOTOXIC SHOCK was established intravenous injection of ENDOTOXIN into rats,",Side Effect,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/15/2014 23:00:35,,1323890674,7/15/2014 22:59:55,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],model of ENDOTOXIC SHOCK was established by injection of ENDOTOXIN,N/A,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232610,7/16/2014 00:02:48,,1323924816,7/16/2014 00:02:13,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],treated,n/a,201,141,209,156,1,RO-has_causative_agent,903981-FS1,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
503232611,7/15/2014 14:51:23,,1323606314,7/15/2014 14:51:01,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 15:33:18,,1323628889,7/15/2014 15:33:06,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],the prognosis of and,N/a,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 15:48:18,,1323640040,7/15/2014 15:47:44,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],and,n\a,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 16:13:00,,1323659333,7/15/2014 16:12:12,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[PREVENTS],[PREVENTS],the classification,asd,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 17:25:41,,1323730398,7/15/2014 17:24:25,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 17:31:26,,1323735135,7/15/2014 17:30:35,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]","this article studies, epidemiologic evidence causation,",N/A,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 18:07:10,,1323764618,7/15/2014 18:06:33,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES] [SIDE_EFFECT] [PART_OF],"[CAUSES]
[SIDE_EFFECT]
[PART_OF]",SEIZURES and EPILEPSY,N/A,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 18:21:00,,1323769424,7/15/2014 18:20:18,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prognosis of SEIZURES and EPILEPSY,N/A,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 18:57:31,,1323786215,7/15/2014 18:57:26,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 19:03:59,,1323790114,7/15/2014 19:02:56,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[OTHER],[OTHER],role genetic factors,not applicable,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 19:57:00,,1323812736,7/15/2014 19:56:24,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],the prognosis of,N/A,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 20:43:27,,1323831708,7/15/2014 20:42:58,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],the prognosis of SEIZURES and EPILEPSY,N/A,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 21:43:39,,1323855914,7/15/2014 21:42:46,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prognosis of SEIZURES and EPILEPSY,n/a,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 22:00:43,,1323862426,7/15/2014 22:00:06,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[PREVENTS],[PREVENTS],EPILEPSY,NONE,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232611,7/15/2014 22:07:47,,1323865602,7/15/2014 22:07:30,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prognosis of SEIZURES and EPILEPSY,n/a,387,400,394,408,-1,RO-has_definitional_manifestation,904831-FS1,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
503232612,7/15/2014 15:35:25,,1323630336,7/15/2014 15:33:50,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[CAUSES] [TREATS],"[TREATS]
[CAUSES]",is contributing on the better prognosis after treatment for,is contributing on the better prognosis after treatment for,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 15:42:17,,1323635448,7/15/2014 15:40:52,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],definition,N/A,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 16:03:47,,1323651976,7/15/2014 16:03:00,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],and,asd,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 16:14:58,,1323660978,7/15/2014 16:13:27,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],its generalization is contributing,N/A,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 16:46:38,,1323697151,7/15/2014 16:45:49,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],systemic response,n/a,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 17:14:36,,1323724453,7/15/2014 17:13:07,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the definition of SEPSIS,na,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 17:45:59,,1323748776,7/15/2014 17:45:47,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 18:22:08,,1323769756,7/15/2014 18:21:29,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],Both concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and SEPSIS been overwhelming,N/A,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 18:39:18,,1323776717,7/15/2014 18:38:26,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the definition of SEPSIS,n/a,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 18:42:51,,1323778454,7/15/2014 18:42:07,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],Both the concept of and the definition of,N/A,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 20:17:16,,1323821177,7/15/2014 20:15:59,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Both the concept and the definition,N/A,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 21:46:48,,1323856931,7/15/2014 21:46:21,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"as the systemic response to infection,",n/a,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 21:59:25,,1323861740,7/15/2014 21:59:11,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[TREATS],[TREATS],SYSTEMIC INFLAMMATORY RESPONSE,NONE,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 22:14:33,,1323868578,7/15/2014 22:12:39,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the definition of,n/a,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232612,7/15/2014 22:27:59,,1323874789,7/15/2014 22:27:07,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Both SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the definition of SEPSIS,N/A,20,89,58,95,-1,RO-cause_of,900115-FS1,"Both the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) and the definition of SEPSIS as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
503232613,7/15/2014 14:44:41,,1323603637,7/15/2014 14:44:03,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],"abnormalities,",N/A,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 14:59:59,,1323609588,7/15/2014 14:59:24,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[SYMPTOM],[SYMPTOM],exhibit,na,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 15:26:03,,1323623605,7/15/2014 15:25:43,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],"exhibit a complex of somatic abnormalities, termed",N/A,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 15:27:18,,1323624414,7/15/2014 15:27:05,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],termed,N/A,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 15:36:50,,1323631426,7/15/2014 15:36:36,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],"exhibit a complex of somatic abnormalities, termed",N/a,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 15:46:58,,1323639029,7/15/2014 15:45:18,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],"complex of abnormalities, termed",N/A,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 15:59:34,,1323648577,7/15/2014 15:58:57,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],termed,N/A,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 16:18:40,,1323664321,7/15/2014 16:17:13,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[CAUSES],[CAUSES],"complex of somatic abnormalities,",It causes some complex abnormalities as stated in the line,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 16:33:49,,1323682188,7/15/2014 16:33:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],termed,N/A,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 16:46:10,,1323696638,7/15/2014 16:45:44,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[SYMPTOM],[SYMPTOM],exhibit,N/A,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 16:50:33,,1323701475,7/15/2014 16:49:50,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[MANIFESTATION],[MANIFESTATION],exhibit,N/A,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 16:54:50,,1323706013,7/15/2014 16:54:07,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[SYMPTOM],[SYMPTOM],"exhibit a complex of somatic abnormalities,",na,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 17:20:14,,1323727387,7/15/2014 17:19:22,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[SYMPTOM],[SYMPTOM],"complex of somatic abnormalities,",na,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 18:26:59,,1323771861,7/15/2014 18:26:49,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SIDE_EFFECT],[SIDE_EFFECT],PHP,n/a,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232613,7/15/2014 18:56:20,,1323785598,7/15/2014 18:56:14,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,an,72,14,111,20,-1,RO-has_manifestation,906061-FS1,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
503232614,7/15/2014 14:46:53,,1323604613,7/15/2014 14:46:13,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[PREVENTS],[PREVENTS],prevent,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 14:47:54,,1323605033,7/15/2014 14:47:44,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],30,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 15:01:19,,1323610249,7/15/2014 15:00:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],estimated to prevent,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 15:02:19,,1323610763,7/15/2014 15:02:05,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",prevent,Na,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 15:05:08,,1323612080,7/15/2014 15:04:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],prevent,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 15:51:01,,1323642139,7/15/2014 15:50:30,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PREVENTS],[PREVENTS],estimated to prevent,n\a,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 16:10:03,,1323656992,7/15/2014 16:09:18,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[SYMPTOM],[SYMPTOM],FONDAPARINUX,asd,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 16:31:38,,1323679847,7/15/2014 16:31:07,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS],[PREVENTS],was estimated to prevent,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 16:32:32,,1323680804,7/15/2014 16:31:36,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[PREVENTS],[PREVENTS],estimated to prevent,n/a,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 16:38:50,,1323688302,7/15/2014 16:38:25,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 16:39:31,,1323689059,7/15/2014 16:38:55,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[PREVENTS],[PREVENTS],prevent,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 17:15:04,,1323724760,7/15/2014 17:14:48,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],compared,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 17:42:42,,1323745588,7/15/2014 17:42:24,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],enoxaparin; produced,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 17:47:21,,1323750010,7/15/2014 17:46:27,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],enoxaparin;,n/a,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232614,7/15/2014 18:01:25,,1323762245,7/15/2014 18:00:40,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],prevent THROMBOEMBOLIC EVENTS FONDAPARINUX,N/A,72,154,92,166,1,RO-may_prevent,907030-FS1,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
503232615,7/15/2014 14:52:45,,1323606780,7/15/2014 14:52:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",results of,N/A,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 15:07:28,,1323613130,7/15/2014 15:06:59,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],CONGESTIVE HEART FAILURE: ENALAPRIL survival study,Unclear,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 15:40:33,,1323634222,7/15/2014 15:39:47,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],Effects of,n/a,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 15:46:37,,1323638823,7/15/2014 15:46:06,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],results of the cooperative survival study,N/A,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 15:47:44,,1323639639,7/15/2014 15:46:20,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[OTHER],[OTHER],results of the cooperative study,N/A,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 16:09:26,,1323656543,7/15/2014 16:08:38,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",Effects of enalapril on,N/A,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 16:48:48,,1323699489,7/15/2014 16:48:31,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],Effects of,N/A,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 17:39:49,,1323742909,7/15/2014 17:39:27,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,Na,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 18:28:07,,1323772456,7/15/2014 18:28:00,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],the,n/a,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 19:19:51,,1323798221,7/15/2014 19:19:22,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SIDE_EFFECT],[SIDE_EFFECT],Effects survival study,not applicable,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 20:06:05,,1323816772,7/15/2014 20:04:35,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],Effects of enalapril on mortality in severe,N/A,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 21:47:06,,1323857040,7/15/2014 21:46:48,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],results of the cooperative North Scandinavian ENALAPRIL survival study,n/a,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 22:01:14,,1323862666,7/15/2014 22:01:03,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[CAUSES],[CAUSES],HEART FAILURE:,NONE,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 22:32:41,,1323877096,7/15/2014 22:32:11,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],results of,N/A,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232615,7/15/2014 22:36:15,,1323879121,7/15/2014 22:35:25,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL,N/A,44,116,67,125,1,RO-may_treat,907551-FS1,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
503232616,7/15/2014 14:55:26,,1323607827,7/15/2014 14:55:01,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 15:11:27,,1323614915,7/15/2014 15:10:38,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],Pyruvate dehydrogenase deficiency is known to account for,N/A,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 15:23:20,,1323621771,7/15/2014 15:22:56,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],known to account for and,N/A,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 16:10:18,,1323657170,7/15/2014 16:09:28,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],known to account for,N/A,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 16:43:34,,1323693638,7/15/2014 16:42:52,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[NONE],[NONE],N/A,two separate conditions,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 17:22:31,,1323728515,7/15/2014 17:22:16,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 17:24:46,,1323729797,7/15/2014 17:24:02,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],known account,n/a,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 18:06:12,,1323764275,7/15/2014 18:05:05,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[SIDE_EFFECT],[SIDE_EFFECT],and,N/A,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 18:11:40,,1323766283,7/15/2014 18:11:04,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]",CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,N/A,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 18:46:20,,1323780219,7/15/2014 18:45:54,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],and,N/A,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 18:54:40,,1323784698,7/15/2014 18:54:10,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,N/A,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 19:10:07,,1323793184,7/15/2014 19:09:20,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,They are caused by a similar factor but have no relation.,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 20:39:49,,1323830338,7/15/2014 20:39:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],lactic acidosis is known to account for,N/A,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 21:32:00,,1323852191,7/15/2014 21:30:26,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,N/A,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232616,7/15/2014 21:45:29,,1323856499,7/15/2014 21:45:01,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,no definite relation,145,193,187,217,-1,RO-has_manifestation,906187-FS1,Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA and INFANTILE LEIGH SYNDROME,CONGENITAL LACTIC ACIDOSIS RECURRENT ATAXIA,INFANTILE LEIGH SYNDROME
503232617,7/15/2014 14:46:50,,1323604584,7/15/2014 14:46:42,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(ventricular,N/A,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 15:17:06,,1323617871,7/15/2014 15:16:51,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],include,N/A,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 15:21:34,,1323620545,7/15/2014 15:21:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],include,N/A,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 15:25:06,,1323622908,7/15/2014 15:24:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],include,N/A,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 15:36:23,,1323631137,7/15/2014 15:35:52,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],include,n/a,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 15:49:27,,1323640851,7/15/2014 15:49:12,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],include,n/a,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 15:59:06,,1323648235,7/15/2014 15:57:57,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TACHYCARDIAS,asd,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 16:44:05,,1323694107,7/15/2014 16:43:51,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],include,N/A,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 16:47:44,,1323698334,7/15/2014 16:47:16,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],include,n/a,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 17:18:08,,1323726326,7/15/2014 17:16:23,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TACHYCARDIAS include SVT,na,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 18:01:49,,1323762440,7/15/2014 18:01:35,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[PART_OF],[PART_OF],include,n/a,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 18:04:00,,1323763166,7/15/2014 18:03:29,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA),N/A,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 18:18:41,,1323768655,7/15/2014 18:18:19,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[IS_A],[IS_A],TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA),N/A,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 18:56:59,,1323785898,7/15/2014 18:56:53,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232617,7/15/2014 20:43:42,,1323831814,7/15/2014 20:43:28,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],include,N/A,0,21,11,55,-1,RO-has_definitional_manifestation,904561-FS1,TACHYCARDIAS include SVT (SUPRAVENTRICULAR TACHYCARDIA) and VT (ventricular tachycardia.,TACHYCARDIAS,SVT (SUPRAVENTRICULAR TACHYCARDIA)
503232618,7/15/2014 14:46:41,,1323604513,7/15/2014 14:46:33,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],large,N/A,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 14:51:33,,1323606368,7/15/2014 14:50:55,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SIDE_EFFECT],[SIDE_EFFECT],may produce simulating,N/A,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 15:01:16,,1323610202,7/15/2014 15:01:01,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],simulating,Na,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 15:01:47,,1323610479,7/15/2014 15:01:25,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],"SPONTANEOUS ADRENAL HEMORRHAGE may produce masses, simulating NEUROBLASTOMA",N/A,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 15:20:13,,1323619658,7/15/2014 15:18:48,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[NONE],[NONE],N/A,"The two issues presented can be mistaken for one another, but do not directly have anything to do with each other and, as such, have no discernible relationship.",28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 15:22:47,,1323621400,7/15/2014 15:22:35,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],"may produce large adrenal masses, simulating",N/A,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 15:36:10,,1323630941,7/15/2014 15:35:46,instagc,1,18960682,GBR,"","",86.29.147.112,[OTHER],[OTHER],simulating,N/a,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 16:12:51,,1323659183,7/15/2014 16:10:18,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[NONE],[NONE],N/A,"The two terms present similar appearances, leading to one being mistaken for the other, but are not otherwise related, except possibly in being in a similar location (?)",28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 17:03:47,,1323716126,7/15/2014 17:01:17,prodege,1,2767509,CAN,BC,Victoria,96.54.172.117,[NONE],[NONE],N/A,"The mass produced by the Spontaneous Adrenal Hemorrhage is said to only simulate a  Neuroblastoma, so there is no direct connection.",28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 17:47:59,,1323750607,7/15/2014 17:47:46,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[CAUSES],[CAUSES],simulating,N/A,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 17:56:03,,1323758901,7/15/2014 17:54:59,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],SPONTANEOUS ADRENAL HEMORRHAGE simulating NEUROBLASTOMA,N/A,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 18:44:44,,1323779467,7/15/2014 18:44:07,neodev,1,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],simulating,N/A,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 20:51:54,,1323835185,7/15/2014 20:50:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],simulating,One is similar to the other.,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 22:23:42,,1323872827,7/15/2014 22:22:41,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[SIDE_EFFECT],[SIDE_EFFECT],may produce,N/A,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232618,7/15/2014 22:31:43,,1323876576,7/15/2014 22:30:47,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",SPONTANEOUS ADRENAL HEMORRHAGE simulating NEUROBLASTOMA,N/A,28,104,57,117,-1,RO-disease_may_have_finding,902782-FS1,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
503232619,7/15/2014 14:49:43,,1323605702,7/15/2014 14:48:45,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],selected,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 15:28:01,,1323624956,7/15/2014 15:27:42,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Because montelukast is efficacious for patients with may be good candidates for,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 16:34:26,,1323682922,7/15/2014 16:33:26,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",may be good candidates for,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 16:46:01,,1323696501,7/15/2014 16:45:33,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],may be good candidates for,na,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 16:51:04,,1323701961,7/15/2014 16:48:50,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],with ASTHMA may be good candidates for MONTELUKAST.,No option for Treated By,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 17:20:45,,1323727703,7/15/2014 17:20:29,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],good candidates,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 17:35:10,,1323738522,7/15/2014 17:34:37,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],efficacious,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 17:46:10,,1323748867,7/15/2014 17:46:00,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],may be good candidates,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 18:13:01,,1323766715,7/15/2014 18:12:16,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[TREATS],[TREATS],may be good candidates for MONTELUKAST.,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 18:32:17,,1323773919,7/15/2014 18:31:39,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],may be good candidates,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 18:56:28,,1323785692,7/15/2014 18:55:42,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],montelukast is efficacious for patients with ASTHMA,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 20:18:28,,1323821750,7/15/2014 20:17:16,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],is efficacious for patients,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 20:50:11,,1323834524,7/15/2014 20:49:52,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],efficacious,/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 22:02:43,,1323863345,7/15/2014 22:02:34,neodev,1,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[LOCATION],[LOCATION],patients,NONE,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232619,7/15/2014 22:22:26,,1323872160,7/15/2014 22:21:39,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",ASTHMA good candidates for MONTELUKAST.,N/A,53,135,58,146,1,RO-may_treat,907799-FS1,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
503232620,7/15/2014 14:48:06,,1323605113,7/15/2014 14:47:55,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],effects,N/A,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 14:50:27,,1323605965,7/15/2014 14:49:52,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CONTRAINDICATES],[CONTRAINDICATES],can exert favorable effects,N/A,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 15:21:52,,1323620732,7/15/2014 15:21:33,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],on BONE,N/A,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 15:42:37,,1323635709,7/15/2014 15:41:25,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[SIDE_EFFECT],[SIDE_EFFECT],exert favorable effects on,[SIDE_EFFECT],56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 15:45:57,,1323638330,7/15/2014 15:45:35,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],on BONE,n/a,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 16:33:25,,1323681804,7/15/2014 16:33:08,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],can exert,N/A,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 16:54:27,,1323705586,7/15/2014 16:52:16,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[LOCATION],[LOCATION],OSTEOPOROSIS on BONE,na,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 17:22:31,,1323728492,7/15/2014 17:22:06,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SIDE_EFFECT],[SIDE_EFFECT],favorable effects,n/a,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 17:56:15,,1323759045,7/15/2014 17:56:01,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[LOCATION],[LOCATION],effects on,n/a,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 18:01:01,,1323762106,7/15/2014 17:59:49,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[OTHER],[OTHER],exert favorable effects,N/A,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 18:07:45,,1323764834,7/15/2014 18:07:12,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],OSTEOPOROSIS effects BONE size,N/A,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 18:32:29,,1323773977,7/15/2014 18:30:40,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[LOCATION],[LOCATION],OSTEOPOROSIS on BONE,N/A,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 18:35:03,,1323774805,7/15/2014 18:34:29,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],OSTEOPOROSIS medications can exert favorable effects,N/A,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 19:52:38,,1323811298,7/15/2014 19:52:00,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],effects on,N/A,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232620,7/15/2014 21:50:18,,1323858087,7/15/2014 21:50:01,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],OSTEOPOROSIS medications exert favorable effects on BONE size,n/a,56,0,59,12,1,RO-disease_has_primary_anatomic_site,902388-FS1,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
503232621,7/15/2014 14:56:54,,1323608457,7/15/2014 14:56:30,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed by positive test.,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 15:04:40,,1323611899,7/15/2014 15:04:25,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MYASTHENIA GRAVIS confirmed by NEOSTIGMINE test.,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 15:32:28,,1323628203,7/15/2014 15:32:15,instagc,1.0,18960682,GBR,"","",86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was confirmed by a positive,N/a,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 15:36:10,,1323630930,7/15/2014 15:35:58,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test.,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 15:58:56,,1323648120,7/15/2014 15:58:26,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was confirmed by a test.,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 16:46:04,,1323696563,7/15/2014 16:45:39,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test.,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 17:56:37,,1323759436,7/15/2014 17:56:15,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed by a positive,n/a,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 18:10:17,,1323765906,7/15/2014 18:09:25,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[OTHER],[OTHER],confirmed positive test.,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 18:29:03,,1323772845,7/15/2014 18:28:57,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],positive,n/a,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 18:34:04,,1323774482,7/15/2014 18:33:47,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MYASTHENIA GRAVIS was confirmed by NEOSTIGMINE test.,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 21:42:09,,1323855400,7/15/2014 21:41:55,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was confirmed by a positive test.,n/a,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 21:44:48,,1323856279,7/15/2014 21:44:19,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was confirmed by a positive NEOSTIGMINE test.,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 22:26:05,,1323873910,7/15/2014 22:25:33,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MYASTHENIA GRAVIS confirmed a positive NEOSTIGMINE,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 23:05:22,,1323893954,7/15/2014 23:04:13,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MYASTHENIA GRAVIS confirmed positive NEOSTIGMINE test.,Diagnosed by test or drug,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232621,7/15/2014 23:17:18,,1323900542,7/15/2014 23:16:27,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MYASTHENIA GRAVIS was confirmed by NEOSTIGMINE test.,N/A,0,46,16,57,1,RO-may_diagnose,906866-FS1,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
503232622,7/15/2014 14:46:32,,1323604486,7/15/2014 14:46:21,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],Podophyllin,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 14:47:50,,1323605013,7/15/2014 14:47:24,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 14:50:54,,1323606116,7/15/2014 14:50:22,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treatment of,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 15:27:04,,1323624266,7/15/2014 15:26:53,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],for the self treatment of,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 15:33:42,,1323629156,7/15/2014 15:33:26,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],self treatment of,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 15:48:04,,1323639875,7/15/2014 15:47:48,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment of,n/a,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 16:38:07,,1323687366,7/15/2014 16:37:55,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 17:49:26,,1323752035,7/15/2014 17:49:16,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],treatment,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 18:17:41,,1323768311,7/15/2014 18:17:21,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[TREATS],[TREATS],PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS:,n/a,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 18:27:30,,1323772134,7/15/2014 18:27:24,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],Podophyllin,n/a,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 18:33:17,,1323774265,7/15/2014 18:32:31,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS:,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 18:36:52,,1323775616,7/15/2014 18:36:29,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],self treatment,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 20:19:55,,1323822314,7/15/2014 20:19:14,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],for the self treatment of,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 20:44:17,,1323832098,7/15/2014 20:43:43,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],for the self treatment of,N/A,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232622,7/15/2014 21:38:22,,1323854158,7/15/2014 21:37:35,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[OTHER],[OTHER],for the self treatment of,Is treated by,151,104,162,119,1,RO-may_treat,907713-FS1,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
503232623,7/15/2014 14:51:30,,1323606360,7/15/2014 14:50:55,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is,N/A,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 15:21:12,,1323620315,7/15/2014 15:20:54,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 15:29:25,,1323626020,7/15/2014 15:28:55,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],as sole therapy for,[DIAGNOSE_BY_TEST_OR_DRUG],63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 15:47:35,,1323639494,7/15/2014 15:46:58,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Different conditions,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 15:48:19,,1323640041,7/15/2014 15:47:45,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for or,N/A,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 15:51:23,,1323642377,7/15/2014 15:50:56,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,different conditions,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 16:51:51,,1323702849,7/15/2014 16:51:36,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 17:13:22,,1323723821,7/15/2014 17:11:00,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[NONE],[NONE],N/A,"Two diabetic conditions, but the sentence does not show them as related.",63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 17:17:54,,1323726196,7/15/2014 17:17:32,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[IS_A],[IS_A],or,N/A,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 17:46:31,,1323749164,7/15/2014 17:46:21,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIABETES DIABETIC,N/A,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 17:46:33,,1323749208,7/15/2014 17:45:40,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS;,n/a,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 18:05:04,,1323763870,7/15/2014 18:04:27,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[IS_A],[IS_A],TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS;,N/A,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 18:08:08,,1323764982,7/15/2014 18:07:43,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS] [SYMPTOM],"[TREATS]
[SYMPTOM]",Not effective sole therapy insulin necessary.,n/a,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 18:12:20,,1323766469,7/15/2014 18:11:41,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES] [PART_OF],"[CAUSES]
[PART_OF]",TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS;,N/A,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232623,7/15/2014 18:30:39,,1323773374,7/15/2014 18:28:15,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[NONE],[NONE],N/A,Part sentence stating a particular treatment is not solely suitable for either of these conditions.,63,35,83,59,-1,RO-cause_of,900005-FS1,Not  effective as sole therapy for TYPE 1 DIABETES MELLITUS or DIABETIC KETOACIDOSIS; insulin is necessary.,DIABETIC KETOACIDOSIS,TYPE 1 DIABETES MELLITUS
503232624,7/15/2014 14:40:02,,1323601952,7/15/2014 14:39:23,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],classifiable,na,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 15:04:04,,1323611619,7/15/2014 15:03:32,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],NON IHS MIGRAINE (not classifiable as migraine or IHS TENSION TYPE HEADACHE,'Not including' relation,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 15:18:07,,1323618452,7/15/2014 15:17:18,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],or,Both are types of headaches but there is no direct relation between the two types.,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 15:32:42,,1323628398,7/15/2014 15:32:07,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[OTHER],[OTHER],"Of these headaches,",N/A,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 15:41:23,,1323634734,7/15/2014 15:40:41,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],114 were classified per IHS,[DIAGNOSE_BY_TEST_OR_DRUG],154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 16:26:02,,1323672488,7/15/2014 16:23:46,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],classified as migraine;,N/A,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 16:41:11,,1323691072,7/15/2014 16:40:14,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE,n/a,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 16:46:55,,1323697572,7/15/2014 16:46:10,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[OTHER],[OTHER],(not classifiable as,N/A,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 17:15:19,,1323724915,7/15/2014 17:15:00,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[IS_A],[IS_A],MIGRAINE HEADACHE,na,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 17:18:34,,1323726516,7/15/2014 17:17:54,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[OTHER],[OTHER],or,N/A,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 17:20:29,,1323727556,7/15/2014 17:19:45,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were classified,N/A,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 18:05:53,,1323764180,7/15/2014 18:05:09,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],classified classifiable,n/a,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 18:24:25,,1323770869,7/15/2014 18:22:39,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[OTHER],[OTHER],NON IHS MIGRAINE (not classifiable as IHS migraine,n/a,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 18:26:05,,1323771468,7/15/2014 18:25:59,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],114,n/a,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232624,7/15/2014 18:28:29,,1323772621,7/15/2014 18:27:31,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[IS_A],[IS_A],"Of these headaches, 42 NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",N/A,154,100,178,116,-1,RO-has_definitional_manifestation,904728-FS1,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension type; and 42 as NON IHS MIGRAINE (not classifiable as IHS migraine or IHS TENSION TYPE HEADACHE",IHS TENSION TYPE HEADACHE,NON IHS MIGRAINE
503232625,7/15/2014 14:53:44,,1323607193,7/15/2014 14:53:22,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],forms of hypertension,N/A,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 14:58:18,,1323608959,7/15/2014 14:57:56,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[IS_A],[IS_A],principally include,na,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 15:26:17,,1323623738,7/15/2014 15:25:38,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related to overindulgence.,[ASSOCIATED_WITH],132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 15:45:24,,1323637919,7/15/2014 15:44:46,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,N/A,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 16:16:20,,1323662193,7/15/2014 16:15:00,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER] [IS_A],"[IS_A]
[OTHER]",forms of hypertension principally include,N/A,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 16:43:36,,1323693657,7/15/2014 16:43:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,N/A,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 17:21:04,,1323727824,7/15/2014 17:20:46,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],include,N/A,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 17:45:37,,1323748352,7/15/2014 17:43:25,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"hyperaldosteronism, hypercortisolism,",n/a,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 18:01:13,,1323762205,7/15/2014 18:00:57,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[PART_OF],[PART_OF],include,n/a,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 18:04:45,,1323763755,7/15/2014 18:04:01,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],include PHEOCHROMOCYTOMA HYPERTENSION,N/A,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 18:26:34,,1323771664,7/15/2014 18:26:03,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A],[IS_A],forms of hypertension principally include,N/A,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 18:36:06,,1323775284,7/15/2014 18:35:35,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,N/A,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 18:56:52,,1323785854,7/15/2014 18:56:46,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,an,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 19:08:59,,1323792625,7/15/2014 19:08:12,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,They are different types of hypertension.,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232625,7/15/2014 19:10:19,,1323793272,7/15/2014 19:09:45,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[IS_A],[IS_A],nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA,N/A,132,66,143,82,1,RO-disease_may_have_finding,902705-FS1,"The secondary, nonrenal forms of hypertension principally include PHEOCHROMOCYTOMA hyperaldosteronism, hypercortisolism, iatrogenic HYPERTENSION following medication, and hypertension related to overindulgence.",HYPERTENSION,PHEOCHROMOCYTOMA
503232626,7/15/2014 14:41:13,,1323602320,7/15/2014 14:40:39,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treated in,N/A,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 14:57:57,,1323608846,7/15/2014 14:57:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treated patients.,N/A,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 15:25:21,,1323623107,7/15/2014 15:24:47,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],treated patients.,N/A,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 15:45:36,,1323638076,7/15/2014 15:45:17,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],treated patients,N/a,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 16:03:29,,1323651725,7/15/2014 16:01:28,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS],[PREVENTS],risk of death consistently lower,N/A,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 16:39:59,,1323689619,7/15/2014 16:39:44,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was,N/A,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 16:49:46,,1323700610,7/15/2014 16:49:10,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[NONE],[NONE],N/A,separate,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 16:56:11,,1323707575,7/15/2014 16:55:43,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treated,n/a,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 17:20:03,,1323727305,7/15/2014 17:19:47,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],in,N/A,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 18:00:56,,1323762053,7/15/2014 18:00:15,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],treated,is treated by,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 18:28:24,,1323772566,7/15/2014 18:28:17,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],HEPARIN,n/a,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 18:56:32,,1323785710,7/15/2014 18:56:27,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 19:45:57,,1323809156,7/15/2014 19:45:20,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],treated,N/A,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 21:42:29,,1323855563,7/15/2014 21:42:09,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],was consistently approximately lower in enoxaparin treated patients than in HEPARIN treated patients.,n/a,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232626,7/15/2014 22:18:13,,1323870300,7/15/2014 22:17:31,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],was consistently approximately 20% lower in,n/a,70,172,90,179,1,RO-may_treat,908250-FS1,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
503232627,7/15/2014 14:45:14,,1323603921,7/15/2014 14:44:41,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],improve some aspects,N/A,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 15:27:34,,1323624609,7/15/2014 15:26:50,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],improve some aspects,N/a,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 15:48:39,,1323640297,7/15/2014 15:48:18,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],improve some aspects,n\a,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 16:49:06,,1323699787,7/15/2014 16:48:40,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[TREATS],[TREATS],improve,N/A,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 16:54:54,,1323706107,7/15/2014 16:54:22,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],drugs,n/a,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 17:38:23,,1323741615,7/15/2014 17:36:44,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],improve aspects,N/A,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 17:43:49,,1323746481,7/15/2014 17:43:37,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],improve,N/A,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 17:56:19,,1323759087,7/15/2014 17:54:32,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",Atypical antipsychotic drugs (APDs),n/a,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 17:58:40,,1323761143,7/15/2014 17:58:01,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[TREATS],[TREATS],improve,N/A,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 18:03:28,,1323762992,7/15/2014 18:03:07,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],CLOZAPINE improve SCHIZOPHRENIA,N/A,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 18:27:07,,1323771921,7/15/2014 18:27:00,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],but,n/a,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 18:56:06,,1323785479,7/15/2014 18:56:01,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 19:15:56,,1323796039,7/15/2014 19:15:32,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],CLOZAPINE improve some aspects of cognition in SCHIZOPHRENIA,N/A,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 21:49:17,,1323857721,7/15/2014 21:48:54,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],improve some aspects of cognition,n/a,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232627,7/15/2014 22:03:51,,1323863782,7/15/2014 22:03:29,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],improve some aspects of cognition in,n/a,128,44,140,53,1,RO-may_treat,908255-FS1,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
503232628,7/15/2014 14:54:40,,1323607594,7/15/2014 14:54:26,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treated with,N/A,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 15:43:19,,1323636218,7/15/2014 15:42:38,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[TREATS],[TREATS],treated with,N/A,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 16:04:50,,1323652837,7/15/2014 16:03:52,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[SYMPTOM],[SYMPTOM],CLINDAMYCIN.,asd,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 16:50:41,,1323701589,7/15/2014 16:50:10,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treated with,n/a,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 17:19:21,,1323726904,7/15/2014 17:18:10,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],treated with,na,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 18:18:47,,1323768670,7/15/2014 18:17:45,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],treated with,N/A,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 18:45:54,,1323779985,7/15/2014 18:45:32,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],treated with,N/A,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 21:49:30,,1323857749,7/15/2014 21:49:18,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],treated with,n/a,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 21:59:54,,1323862001,7/15/2014 21:59:26,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[PREVENTS],[PREVENTS],METRONIDAZOLE,NONE,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 22:00:51,,1323862493,7/15/2014 22:00:10,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],treated with,n/a,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 22:21:03,,1323871548,7/15/2014 22:19:43,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.,N/A,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 22:30:43,,1323876156,7/15/2014 22:30:23,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[TREATS],[TREATS],treated with,N/A,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 23:02:06,,1323891583,7/15/2014 23:01:09,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.,Treats,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 23:15:30,,1323899571,7/15/2014 23:13:22,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[TREATS],[TREATS],BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.,N/A,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232628,7/15/2014 23:59:07,,1323922699,7/15/2014 23:58:21,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],treated,n/a,72,105,90,147,1,RO-may_treat,907961-FS1,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
503232629,7/15/2014 14:48:27,,1323605270,7/15/2014 14:48:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for the treatment of,N/A,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 14:50:30,,1323605981,7/15/2014 14:50:01,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],efficacy of,na,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 15:29:49,,1323626331,7/15/2014 15:29:27,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[TREATS],[TREATS],for the treatment of,[TREATS],117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 16:35:41,,1323684418,7/15/2014 16:35:14,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],for the treatment of,na,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 17:19:43,,1323727104,7/15/2014 17:17:15,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],treatment,N/A,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 18:42:06,,1323778047,7/15/2014 18:41:30,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",about the efficacy of the for the treatment,N/A,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 19:23:00,,1323799580,7/15/2014 19:20:33,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,N/A,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 20:49:52,,1323834399,7/15/2014 20:49:35,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],for the treatment of,N/A,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 21:40:23,,1323854800,7/15/2014 21:40:07,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],for the treatment of,n/a,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 22:01:39,,1323862877,7/15/2014 22:01:29,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[PREVENTS],[PREVENTS],OSTEOPOROSIS,NONE,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 22:04:50,,1323864217,7/15/2014 22:03:52,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],for the treatment of,n/a,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 22:21:39,,1323871774,7/15/2014 22:21:03,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,N/A,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 22:28:20,,1323875001,7/15/2014 22:28:00,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[TREATS],[TREATS],treatment,N/A,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 22:50:55,,1323886018,7/15/2014 22:50:13,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],ACTIVE FORM OF VITAMIN D treatment OSTEOPOROSIS,treats,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232629,7/15/2014 23:09:33,,1323896369,7/15/2014 23:07:17,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",ACTIVE FORM VITAMIN treatment OSTEOPOROSIS,N/A,117,71,128,95,1,RO-may_prevent,907445-FS1,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
503232630,7/15/2014 15:26:00,,1323623560,7/15/2014 15:25:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[IS_A],[IS_A],is an,N/a,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 15:38:21,,1323632573,7/15/2014 15:36:25,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",autoimmune blistering,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 15:47:04,,1323639143,7/15/2014 15:46:30,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],is an,n/a,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 16:15:41,,1323661572,7/15/2014 16:14:44,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],VULGARIS,asd,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 16:31:06,,1323679207,7/15/2014 16:30:27,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],is an,N/A,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 16:44:30,,1323694625,7/15/2014 16:43:39,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[SYMPTOM],[SYMPTOM],is blistering,N/A,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 16:46:46,,1323697333,7/15/2014 16:46:32,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],OF THE SKIN,N/A,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 18:23:13,,1323770438,7/15/2014 18:22:53,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],OF THE SKIN AND MUCOUS MEMBRANES,N/A,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 18:56:45,,1323785802,7/15/2014 18:56:40,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 19:51:59,,1323811081,7/15/2014 19:51:24,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],is an autoimmune blistering DISEASE OF THE,N/A,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 20:39:23,,1323830195,7/15/2014 20:38:59,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],DISEASE OF THE SKIN,N/A,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 22:02:55,,1323863448,7/15/2014 22:02:44,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MUCOUS MEMBRANES,NONE,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 22:06:58,,1323865218,7/15/2014 22:06:21,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],is an autoimmune blistering DISEASE,n/a,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 22:39:18,,1323880690,7/15/2014 22:38:21,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],PEMPHIGUS VULGARIS DISEASE OF THE SKIN AND MUCOUS MEMBRANES is caused,N/A,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232630,7/15/2014 22:54:12,,1323887806,7/15/2014 22:53:14,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],PEMPHIGUS VULGARIS blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES,Location,47,0,86,18,1,RO-disease_has_primary_anatomic_site,902397-FS1,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
503232631,7/15/2014 14:46:03,,1323604226,7/15/2014 14:45:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],recurrence risk of four,N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 14:55:43,,1323607934,7/15/2014 14:55:05,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],four COMPLICATIONS,N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 15:01:33,,1323610361,7/15/2014 15:01:17,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],recurrence risk,Na,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 15:17:38,,1323618210,7/15/2014 15:17:03,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],the recurrence risk of four,N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 15:26:07,,1323623618,7/15/2014 15:25:34,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],"four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 15:27:51,,1323624810,7/15/2014 15:27:35,instagc,1.0,18960682,GBR,"","",86.29.147.112,[IS_A],[IS_A],and,N/a,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 15:35:16,,1323630228,7/15/2014 15:34:46,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],risk,N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 15:42:54,,1323635935,7/15/2014 15:42:03,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],risk of four,n/a,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 16:35:22,,1323683992,7/15/2014 16:34:53,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],examines,N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 16:47:14,,1323697892,7/15/2014 16:46:47,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[SYMPTOM],[SYMPTOM],recurrence risk,N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 17:00:55,,1323713154,7/15/2014 16:59:23,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],recurrence risk of four,na,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 17:58:46,,1323761186,7/15/2014 17:58:06,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",risk of COMPLICATIONS OF PREGNANCY: PREECLAMPSIA,N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 18:21:47,,1323769650,7/15/2014 18:19:02,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[IS_A],[IS_A],four COMPLICATIONS OF PREGNANCY: PREECLAMPSIA,N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 19:12:21,,1323794291,7/15/2014 19:11:44,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",recurrence risk,not applicable,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232631,7/15/2014 19:45:19,,1323808940,7/15/2014 19:44:17,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],recurrence,N/A,50,134,75,146,-1,RO-disease_has_finding,901860-FS1,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
503232632,7/15/2014 14:58:22,,1323608974,7/15/2014 14:57:52,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],compared with,N/A,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 14:58:53,,1323609174,7/15/2014 14:58:20,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 15:40:39,,1323634265,7/15/2014 15:39:57,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated in patients with,[DIAGNOSE_BY_TEST_OR_DRUG],141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 15:52:49,,1323643427,7/15/2014 15:52:18,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 16:28:31,,1323675865,7/15/2014 16:27:36,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",investigated in patients with,N/A,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 16:42:36,,1323692572,7/15/2014 16:42:24,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 17:45:39,,1323748459,7/15/2014 17:45:05,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with ATOPIC DERMATITIS and ALLERGIC RHINITIS,n/a,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 18:05:09,,1323763896,7/15/2014 18:04:46,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],ATOPIC DERMATITIS (AD) ALLERGIC RHINITIS,N/A,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 18:09:24,,1323765542,7/15/2014 18:08:17,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[IS_A],[IS_A],ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS,N/A,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 18:30:29,,1323773325,7/15/2014 18:30:05,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],and,N/A,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 18:43:34,,1323778863,7/15/2014 18:41:51,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS,"because they investigated this and saw that both are accuring, so they are associated with that decease!",141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 19:59:44,,1323813800,7/15/2014 19:57:01,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with and,N/A,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 21:59:10,,1323861630,7/15/2014 21:58:59,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[LOCATION],[LOCATION],granulocytes,NONE,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 22:00:09,,1323862149,7/15/2014 21:59:38,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,"Patients with each condition were examined, but that does not make the conditions related to each other.",141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232632,7/15/2014 22:19:42,,1323870973,7/15/2014 22:19:13,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],patients ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS,N/A,141,114,157,136,-1,RO-has_manifestation,906239-FS1,The effect of recombinant human and murine interleukin 5 (IL 5) on granulocytes was investigated in patients with ATOPIC DERMATITIS (AD) and ALLERGIC RHINITIS and compared with those from patients with plaque psoriasis and normal non atopic controls.,ALLERGIC RHINITIS,ATOPIC DERMATITIS (AD)
503232633,7/15/2014 14:39:22,,1323601671,7/15/2014 14:39:06,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],similar rates,na,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 14:41:10,,1323602310,7/15/2014 14:39:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have,N/A,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 14:48:43,,1323605329,7/15/2014 14:47:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was observed,N/A,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 14:52:18,,1323606593,7/15/2014 14:51:56,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar rates,na,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 15:09:35,,1323613979,7/15/2014 15:08:54,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],have similar rates of,N/A,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 15:31:19,,1323627445,7/15/2014 15:31:03,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with have similar rates of,N/a,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 15:47:13,,1323639257,7/15/2014 15:46:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],have similar rates of,n/a,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 15:53:28,,1323643885,7/15/2014 15:52:50,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[SYMPTOM],[SYMPTOM],have similar rates of,n/a,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 16:49:41,,1323700507,7/15/2014 16:48:57,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],have similar rates of,n/a,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 17:14:39,,1323724480,7/15/2014 17:13:33,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recent evidence,N/A,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 18:06:32,,1323764414,7/15/2014 18:05:38,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[MANIFESTATION] [CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",LSIL rates HIGH GRADE CERVICAL DYSPLASIA,N/A,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 18:27:51,,1323772353,7/15/2014 18:26:45,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],women with LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA,n/a,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 18:35:34,,1323775011,7/15/2014 18:35:04,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],have similar rates of,N/A,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 18:57:54,,1323786436,7/15/2014 18:57:49,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232633,7/15/2014 19:15:33,,1323795877,7/15/2014 19:14:47,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,There is no correlation.,96,69,124,73,1,RO-disease_has_finding,901864-FS1,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
503232634,7/15/2014 14:42:29,,1323602931,7/15/2014 14:41:14,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],causative of,N/A,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 14:49:57,,1323605806,7/15/2014 14:49:48,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],causative,N/A,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 15:17:02,,1323617832,7/15/2014 15:16:44,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],causative agent of,N/A,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 15:34:16,,1323629557,7/15/2014 15:33:54,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],the causative agent,N/a,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 15:37:42,,1323632084,7/15/2014 15:37:09,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],causative agent,n\a,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 15:47:55,,1323639797,7/15/2014 15:47:36,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],the causative agent,N/A,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 16:14:39,,1323660724,7/15/2014 16:13:46,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],major virulence,asd,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 16:19:16,,1323664861,7/15/2014 16:18:41,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[PART_OF],[PART_OF],causative agent of,a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 16:51:35,,1323702499,7/15/2014 16:51:22,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],causative,N/A,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 16:58:02,,1323709771,7/15/2014 16:57:37,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[CAUSES],[CAUSES],causative,N/A,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 17:33:23,,1323736924,7/15/2014 17:32:24,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],causative agent,n/a,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 17:45:04,,1323747810,7/15/2014 17:43:59,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[CAUSES],[CAUSES],Pertussis toxin factor of BORDETELLA PERTUSSIS agent of WHOOPING COUGH,n/a,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 17:46:45,,1323749445,7/15/2014 17:46:32,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[CAUSES],[CAUSES],causative,N/A,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 18:03:30,,1323763011,7/15/2014 18:03:13,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[CAUSES],[CAUSES],causative agent,n/a,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232634,7/15/2014 18:07:42,,1323764814,7/15/2014 18:07:08,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES] [SIDE_EFFECT] [PART_OF],"[CAUSES]
[SIDE_EFFECT]
[PART_OF]",causative agent,n/a,47,91,66,105,1,RO-has_causative_agent,903889-FS1,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
503232635,7/15/2014 14:47:23,,1323604866,7/15/2014 14:46:54,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],therapy for,N/A,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 14:56:09,,1323608150,7/15/2014 14:55:29,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[TREATS],[TREATS],in therapy for,na,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 15:03:31,,1323611386,7/15/2014 15:03:17,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,N/A,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 15:06:36,,1323612777,7/15/2014 15:06:14,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],therapy for,N/A,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 15:32:14,,1323628005,7/15/2014 15:31:40,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],in therapy for,N/a,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 15:49:46,,1323641090,7/15/2014 15:49:07,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],in therapy,N/A,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 16:13:26,,1323659738,7/15/2014 16:12:52,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],in therapy for,N/A,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 16:50:18,,1323701242,7/15/2014 16:50:06,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],therapy,N/A,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 16:55:41,,1323706901,7/15/2014 16:54:51,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],in therapy for,na,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 17:38:40,,1323741916,7/15/2014 17:38:23,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,Na,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 18:27:59,,1323772410,7/15/2014 18:27:54,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],Mevinolin,n/a,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 18:46:19,,1323780209,7/15/2014 18:45:43,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[PREVENTS],[PREVENTS],therapy,n/a,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 18:54:09,,1323784411,7/15/2014 18:53:53,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,N/A,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 19:07:05,,1323791485,7/15/2014 19:06:07,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],therapy,not applicable,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232635,7/15/2014 22:08:58,,1323866139,7/15/2014 22:08:27,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],in therapy for,n/a,57,31,105,41,1,RO-may_treat,907609-FS1,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
503232636,7/15/2014 14:47:33,,1323604910,7/15/2014 14:47:24,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],conditioning,N/A,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 15:03:20,,1323611333,7/15/2014 15:03:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,Na,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 15:05:26,,1323612201,7/15/2014 15:05:04,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],IMMUNODEFICIENCY associated with GVHD,N/A,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 15:26:42,,1323624015,7/15/2014 15:26:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 15:44:45,,1323637456,7/15/2014 15:44:10,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with transplantation and the development of,N/A,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 15:46:46,,1323638932,7/15/2014 15:46:17,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with transplantation and the development of,[ASSOCIATED_WITH],173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 15:47:47,,1323639669,7/15/2014 15:47:05,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 16:38:21,,1323687695,7/15/2014 16:38:09,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 17:44:01,,1323746667,7/15/2014 17:43:51,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 18:02:07,,1323762541,7/15/2014 18:01:26,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",IMMUNODEFICIENCY associated GVHD,N/A,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 18:07:07,,1323764583,7/15/2014 18:05:55,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS] [MANIFESTATION],"[TREATS]
[MANIFESTATION]",transplantation development,n/a,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 18:32:10,,1323773884,7/15/2014 18:30:55,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],IMMUNODEFICIENCY associated with development of GVHD,n/a,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 18:36:28,,1323775413,7/15/2014 18:36:07,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 18:50:29,,1323782437,7/15/2014 18:50:05,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232636,7/15/2014 19:08:12,,1323792143,7/15/2014 19:07:31,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",associated with development,not applicable,173,245,188,249,1,RO-disease_has_finding,901989-FS1,"These complications may be related to chemo  or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the IMMUNODEFICIENCY associated with transplantation and the development of GVHD",IMMUNODEFICIENCY,GVHD
503232637,7/15/2014 14:43:48,,1323603357,7/15/2014 14:43:12,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as the presence of,N/A,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 15:02:49,,1323611065,7/15/2014 15:02:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,Na,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 15:08:27,,1323613511,7/15/2014 15:07:56,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],as well as the presence of,N/A,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 15:20:36,,1323619855,7/15/2014 15:19:48,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],as well as the presence of,N/A,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 15:44:24,,1323637208,7/15/2014 15:43:55,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[MANIFESTATION],[MANIFESTATION],the presence of,n\a,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 15:50:56,,1323642062,7/15/2014 15:50:30,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 16:13:26,,1323659739,7/15/2014 16:13:04,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[IS_A],[IS_A],correctly,asd,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 16:41:28,,1323691353,7/15/2014 16:40:56,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],identified,N/A,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 16:57:32,,1323709215,7/15/2014 16:56:56,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/A,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 17:10:58,,1323722167,7/15/2014 17:09:36,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATOMA as well as,na,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 18:14:23,,1323767131,7/15/2014 18:13:38,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[SYMPTOM],[SYMPTOM],"correctly identified by both methods, presence",N/A,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 18:27:31,,1323772148,7/15/2014 18:26:35,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[NONE],[NONE],N/A,only thing is both conditions being found in patients.,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 18:55:14,,1323785042,7/15/2014 18:55:08,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 20:14:24,,1323820132,7/15/2014 20:13:26,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as the presence of,N/A,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232637,7/15/2014 21:26:44,,1323850139,7/15/2014 21:25:01,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as the presence of,N/A,93,0,99,8,1,RO-disease_may_have_finding,902957-FS1,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
503232638,7/15/2014 14:44:34,,1323603628,7/15/2014 14:43:45,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF] [CAUSES],"[CAUSES]
[PART_OF]",caused with,N/A,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 14:48:26,,1323605264,7/15/2014 14:48:18,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],urinary,N/A,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 15:26:48,,1323624127,7/15/2014 15:26:25,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],were reduced in the case with,N/a,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 15:27:31,,1323624553,7/15/2014 15:27:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],were reduced,N/A,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 15:32:35,,1323628345,7/15/2014 15:31:59,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[IS_A],[IS_A],in the case,n\a,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 15:42:11,,1323635378,7/15/2014 15:40:34,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],in the case with,n/a,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 16:51:56,,1323702943,7/15/2014 16:51:10,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[MANIFESTATION],[MANIFESTATION],were reduced in the case with,N/A,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 18:03:12,,1323762895,7/15/2014 18:02:14,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],reduced with,is treated by,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 18:27:45,,1323772308,7/15/2014 18:27:39,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],infections,n/a,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 18:37:47,,1323775986,7/15/2014 18:36:55,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],BACTERIA were reduced in the case with S PANAMA BACTEREMIA,n/a,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 18:55:40,,1323785241,7/15/2014 18:55:17,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A],[IS_A],BACTERIA BACTEREMIA,N/A,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 20:15:58,,1323820679,7/15/2014 20:14:57,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],were reduced in the case with,N/A,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 21:46:21,,1323856753,7/15/2014 21:45:49,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BACTERIA were reduced in the case with S PANAMA BACTEREMIA,n/a,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 21:52:49,,1323858857,7/15/2014 21:52:19,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],were reduced in the case with,n/a,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232638,7/15/2014 21:57:21,,1323860738,7/15/2014 21:57:10,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[TREATS],[TREATS],BACTERIA,NONE,32,71,39,90,-1,RO-has_causative_agent,903807-FS1,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
503232639,7/15/2014 14:43:02,,1323603095,7/15/2014 14:42:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was diagnosed.,N/A,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 14:43:11,,1323603136,7/15/2014 14:42:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed.,N/A,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 15:00:29,,1323609818,7/15/2014 14:59:58,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],formed,N/A,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 15:43:33,,1323636449,7/15/2014 15:43:01,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[SYMPTOM],[SYMPTOM],diagnosed.,n/a,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 15:46:15,,1323638555,7/15/2014 15:45:46,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",formed an encapsulated mass in,[CAUSES] [MANIFESTATION],13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 16:00:50,,1323649606,7/15/2014 16:00:07,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[TREATS],[TREATS],CALCIUM DEPOSITS,asd,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 16:20:55,,1323666695,7/15/2014 16:20:12,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],formed was diagnosed.,"CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 17:15:22,,1323724919,7/15/2014 17:14:41,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",formed mass,N/A,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 17:26:26,,1323730931,7/15/2014 17:25:43,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],and diagnosed.,n/a,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 18:24:45,,1323770988,7/15/2014 18:24:27,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],EXTRASKELETAL,N/A,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 18:34:28,,1323774620,7/15/2014 18:33:45,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],formed an encapsulated mass and the EXTRASKELETAL OSTEOCHONDROMA,N/A,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 18:38:02,,1323776096,7/15/2014 18:35:36,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[LOCATION] [MANIFESTATION],"[LOCATION]
[MANIFESTATION]","encapsulated mass iliopsoas muscle,",n/a,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 18:38:25,,1323776276,7/15/2014 18:37:48,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],CALCIUM DEPOSITS formed an encapsulated mass and EXTRASKELETAL OSTEOCHONDROMA was diagnosed.,n/a,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 18:55:47,,1323785296,7/15/2014 18:55:42,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,an,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232639,7/15/2014 20:48:24,,1323833869,7/15/2014 20:48:10,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was diagnosed.,N/A,13,91,28,119,1,RO-disease_may_have_finding,902718-FS1,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
503232640,7/15/2014 14:41:31,,1323602470,7/15/2014 14:41:15,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],and,na,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 14:57:56,,1323608844,7/15/2014 14:57:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 15:03:16,,1323611271,7/15/2014 15:03:00,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",N/A,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 15:39:41,,1323633586,7/15/2014 15:39:15,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],hypertension,N/a,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 15:56:59,,1323646669,7/15/2014 15:56:39,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],adrenal,asd,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 16:40:22,,1323690198,7/15/2014 16:40:01,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 16:47:39,,1323698218,7/15/2014 16:46:50,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,they are two different  things,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 17:00:42,,1323712878,7/15/2014 17:00:02,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with and,N/A,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 17:14:12,,1323724293,7/15/2014 17:13:50,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 18:22:52,,1323770306,7/15/2014 18:22:27,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY,N/A,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 18:26:36,,1323771675,7/15/2014 18:26:17,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[OTHER],[OTHER],"female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",N/A,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 18:29:26,,1323772963,7/15/2014 18:29:19,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS],[PREVENTS],1),n/a,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 21:57:31,,1323860805,7/15/2014 21:56:39,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,"They appear to be two separate conditions in the same list, with no relation to each other.",196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 22:23:50,,1323872846,7/15/2014 22:22:27,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY,N/A,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232640,7/15/2014 22:33:31,,1323877575,7/15/2014 22:32:42,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[NONE],[NONE],N/A,They are separate problems.,196,220,214,247,-1,RO-disease_has_finding,901904-FS1,"Two cases are reported as follows: 1) 1 female patient with accelerated malignant hypertension secondary to an aldosterone producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, SEVERE HYPERTENSION and HYPERTENSIVE ENCEPHALOPATHY",SEVERE HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503232641,7/15/2014 15:28:12,,1323625077,7/15/2014 15:28:02,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],SKIN sites,N/A,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 17:29:01,,1323733093,7/15/2014 17:28:12,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],n/a,no relation mentioned,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 17:34:36,,1323738028,7/15/2014 17:33:58,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include pigmented skin,N/A,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 17:45:16,,1323748108,7/15/2014 17:45:06,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],SKIN,N/A,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 17:46:25,,1323749114,7/15/2014 17:45:38,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]","sites actinic keratosis, malignant basal cell carcinoma,",n/a,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 18:19:41,,1323769049,7/15/2014 18:18:48,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],sites,N/A,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 19:05:27,,1323790693,7/15/2014 19:04:28,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],skin sites [nonpigmented,not applicable,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 21:39:36,,1323854540,7/15/2014 21:39:14,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PART_OF],[PART_OF],"unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma,",n/a,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 21:40:07,,1323854694,7/15/2014 21:39:53,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PART_OF],[PART_OF],SKIN sites [nonpigmented INTRADERMAL NEVUS,n/a,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 21:57:09,,1323860656,7/15/2014 21:56:56,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[TREATS],[TREATS],INTRADERMAL,NONE,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 22:34:07,,1323877947,7/15/2014 22:33:32,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[LOCATION],[LOCATION],"SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma,",N/A,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 22:48:40,,1323884787,7/15/2014 22:47:46,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[PART_OF],[PART_OF],SKIN sites INTRADERMAL NEVUS,Part of,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/15/2014 23:05:06,,1323893798,7/15/2014 23:03:24,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS,N/A,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/16/2014 00:02:11,,1323924433,7/16/2014 00:01:03,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],[nonpigmented,n/a,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/16/2014 00:16:14,,1323934095,7/16/2014 00:14:40,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[IS_A],[IS_A],[nonpigmented,I did not select none.,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232641,7/16/2014 00:27:11,,1323939670,7/16/2014 00:25:06,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],sites,N/A,86,111,89,128,1,RO-has_finding_site,905150-FS1,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
503232642,7/15/2014 14:45:51,,1323604145,7/15/2014 14:45:17,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],came in,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 15:01:01,,1323610050,7/15/2014 15:00:32,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],came as a debut of,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 15:04:23,,1323611756,7/15/2014 15:04:05,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[LOCATION],[LOCATION],STROKE abnormalities in the BRAIN,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 15:19:53,,1323619463,7/15/2014 15:19:26,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],came as a debut in the,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 15:22:23,,1323621100,7/15/2014 15:22:09,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],in the BRAIN,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 15:45:07,,1323637744,7/15/2014 15:44:22,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION],[MANIFESTATION],came as a debut of,[MANIFESTATION],84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 16:16:25,,1323662281,7/15/2014 16:15:45,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],STROKE,asd,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 16:43:54,,1323693919,7/15/2014 16:43:38,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],came as a debut,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 17:10:59,,1323722178,7/15/2014 17:10:45,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],in the,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 17:26:50,,1323731244,7/15/2014 17:25:49,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",vascular abnormalities,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 17:54:57,,1323757640,7/15/2014 17:54:10,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],STROKE came in BRAIN,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 18:39:01,,1323776627,7/15/2014 18:37:58,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],came as debut,the STROKE came as a debut of vascular abnormalities in the BRAIN,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 18:40:49,,1323777470,7/15/2014 18:39:56,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[LOCATION],[LOCATION],In most patients the STROKE came as a debut of abnormalities in the BRAIN,n/a,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 18:45:42,,1323779908,7/15/2014 18:44:48,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[LOCATION] [CAUSES],"[CAUSES]
[LOCATION]",came vascular abnormalities,n/a,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232642,7/15/2014 20:53:19,,1323835684,7/15/2014 20:53:07,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],in the BRAIN,N/A,84,28,88,34,1,RO-disease_has_primary_anatomic_site,902042-FS1,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
503232643,7/15/2014 14:57:51,,1323608761,7/15/2014 14:57:00,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],showed,N/A,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 15:00:45,,1323609910,7/15/2014 15:00:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],no,Na,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 15:24:43,,1323622707,7/15/2014 15:24:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],but no,N/a,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 15:42:02,,1323635232,7/15/2014 15:41:25,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],showed but no,n/a,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 16:02:54,,1323651283,7/15/2014 16:00:55,clixsense,1,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],scirrhous,asd,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 16:43:50,,1323693866,7/15/2014 16:43:31,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,[OTHER],[OTHER],but no,N/A,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 16:47:54,,1323698508,7/15/2014 16:46:59,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[NONE],[NONE],N/A,symptoms not found in,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 16:59:22,,1323711553,7/15/2014 16:58:20,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two different things,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 17:32:18,,1323735929,7/15/2014 17:31:27,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Histology showed,N/A,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 17:48:27,,1323751083,7/15/2014 17:48:00,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],showed a scirrhous carcinoma but no,N/A,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 18:02:09,,1323762560,7/15/2014 18:01:02,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[NONE],[NONE],N/A,They are not related.,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 18:20:17,,1323769201,7/15/2014 18:19:42,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],Histology showed but no LYMPH NODE METASTASES,N/A,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 21:47:26,,1323857177,7/15/2014 21:46:11,neodev,1,11087793,GBR,K6,Southsea,82.24.115.185,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"Histology showed a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",N/A,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 22:15:15,,1323868900,7/15/2014 22:14:34,zapbux,1,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],but no,n/a,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232643,7/15/2014 22:17:21,,1323869885,7/15/2014 22:16:37,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PREVENTS],[PREVENTS],MEDULLARY CARCINOMA no LYMPH NODE METASTASES,N/A,105,57,125,76,-1,RO-disease_may_have_finding,902681-FS1,"Histology showed a scirrhous carcinoma of the left and a MEDULLARY CARCINOMA of the right breast, but no LYMPH NODE METASTASES",LYMPH NODE METASTASES,MEDULLARY CARCINOMA
503232644,7/15/2014 15:39:25,,1323633393,7/15/2014 15:38:57,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",control in patients with,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 15:41:26,,1323634790,7/15/2014 15:40:09,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[SYMPTOM],[SYMPTOM],in patients with,N/A,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 18:29:28,,1323772969,7/15/2014 18:28:44,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],increases the chance in patients with,N/A,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 18:39:51,,1323777047,7/15/2014 18:39:02,clixsense,1,27969116,NLD,04,Veendam,185.12.216.74,[CAUSES],[CAUSES],increases the chance,it can cause SEIZURE in patients with EPILEPSY,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 19:00:32,,1323788297,7/15/2014 18:59:46,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[PART_OF],[PART_OF],increases chance of,not applicable,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 19:10:42,,1323793460,7/15/2014 19:10:20,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[MANIFESTATION],[MANIFESTATION],SEIZURE in patients with EPILEPSY,N/A,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 21:58:58,,1323861550,7/15/2014 21:58:37,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SEIZURE,NONE,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 22:37:49,,1323879933,7/15/2014 22:37:10,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],SEIZURE with EPILEPSY,N/A,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 23:03:23,,1323892541,7/15/2014 23:00:36,neodev,1,20929875,USA,MA,Allston,71.174.190.73,[CAUSES] [ASSOCIATED_WITH] [SIDE_EFFECT],"[CAUSES]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",increases chance SEIZURE patients with EPILEPSY,N/A,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 23:04:10,,1323893089,7/15/2014 23:03:14,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURE control patients EPILEPSY,Associated With,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/15/2014 23:59:36,,1323922943,7/15/2014 23:59:09,prodege,1,15439740,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],in,n/a,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/16/2014 00:17:07,,1323934633,7/16/2014 00:16:16,prodege,1,9636318,USA,HI,Wailuku,72.234.78.171,[SIDE_EFFECT],[SIDE_EFFECT],Treatment,I did not select none.,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/16/2014 00:18:19,,1323935339,7/16/2014 00:18:00,clixsense,1,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],increases the chance,N/A,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/16/2014 00:27:40,,1323939831,7/16/2014 00:27:12,bitcoinget,1,21614812,USA,"","",73.39.136.3,[MANIFESTATION],[MANIFESTATION],chance of control,N/A,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232644,7/16/2014 00:32:01,,1323942072,7/16/2014 00:31:27,elite,1,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,SEIZURE control in patients with EPILEPSY,65,98,71,106,-1,RO-has_definitional_manifestation,904589-FS1,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
503232645,7/15/2014 14:49:26,,1323605608,7/15/2014 14:49:16,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],marker,N/A,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 14:50:29,,1323605974,7/15/2014 14:50:01,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],has been evaluated in,N/A,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 15:02:31,,1323610871,7/15/2014 15:01:39,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],marker of,N/A,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 15:24:55,,1323622845,7/15/2014 15:24:45,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has been evaluated in,N/A,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 15:26:24,,1323623823,7/15/2014 15:26:01,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],a marker of,N/a,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 15:37:47,,1323632158,7/15/2014 15:37:23,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],marker,N/a,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 15:39:56,,1323633757,7/15/2014 15:39:27,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has been evaluated in,[DIAGNOSE_BY_TEST_OR_DRUG],66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 15:49:13,,1323640696,7/15/2014 15:48:40,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],marker of,n/a,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 16:09:14,,1323656350,7/15/2014 16:08:58,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],neuron,asd,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 16:34:52,,1323683483,7/15/2014 16:34:40,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluated,N/A,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 16:51:59,,1323703032,7/15/2014 16:51:22,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],has been evaluated in,na,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 17:29:32,,1323733512,7/15/2014 17:29:02,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],evaluated,n/a,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 18:12:15,,1323766459,7/15/2014 18:10:59,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[SIDE_EFFECT],[SIDE_EFFECT],NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER,N/A,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 18:25:09,,1323771141,7/15/2014 18:24:46,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[PART_OF],[PART_OF],has been evaluated in,N/A,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232645,7/15/2014 18:29:48,,1323773072,7/15/2014 18:28:30,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[SYMPTOM],[SYMPTOM],a marker of NEUROENDOCRINE DIFFERENTIATION evaluated SMALL CELL LUNG CANCER,N/A,66,119,95,148,-1,RO-disease_has_finding,901631-FS1,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
503232646,7/15/2014 14:47:38,,1323604920,7/15/2014 14:47:01,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[SYMPTOM],[SYMPTOM],complication of,na,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 14:56:11,,1323608164,7/15/2014 14:55:44,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],complication,N/A,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 15:33:25,,1323628945,7/15/2014 15:32:43,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],complication of,N/A,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 15:39:13,,1323633237,7/15/2014 15:38:47,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[MANIFESTATION],[MANIFESTATION],important complication,N/A,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 15:47:37,,1323639535,7/15/2014 15:46:59,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[MANIFESTATION],[MANIFESTATION],an important complication of,N/A,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 16:12:09,,1323658734,7/15/2014 16:10:57,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[PREVENTS],[PREVENTS],radiotherapy alone,asd,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 16:35:19,,1323683939,7/15/2014 16:33:35,prodege,1,4228517,USA,TX,Fort Worth,99.71.201.172,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",is an important complication of,N/A,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 16:42:52,,1323692821,7/15/2014 16:42:35,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],complication,N/A,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 16:51:21,,1323702268,7/15/2014 16:50:07,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],which is an important complication of,na,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 17:08:30,,1323720237,7/15/2014 17:07:43,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],important complication,na,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 17:17:14,,1323725898,7/15/2014 17:15:23,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],important complication,N/A,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 22:04:33,,1323864070,7/15/2014 22:03:54,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],METASTASES,NONE,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 22:19:13,,1323870727,7/15/2014 22:17:46,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]",PATHOLOGICAL FRACTURE is complication of SPINAL METASTASES,N/A,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 22:30:22,,1323875960,7/15/2014 22:29:19,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],an important complication of,N/A,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232646,7/15/2014 23:01:08,,1323891013,7/15/2014 22:59:43,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SIDE_EFFECT] [LOCATION],"[LOCATION]
[SIDE_EFFECT]",PATHOLOGICAL FRACTURE important complication SPINAL METASTASES,Side Effect / Location,61,121,81,138,1,RO-disease_may_have_finding,902720-FS1,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
503232647,7/15/2014 14:58:37,,1323609096,7/15/2014 14:57:58,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],"treatment of depressive patients,",N/A,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 14:59:57,,1323609589,7/15/2014 14:59:30,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 15:34:45,,1323629847,7/15/2014 15:34:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treatment of,n\a,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 15:48:23,,1323640070,7/15/2014 15:48:04,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment of,n/a,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 16:33:29,,1323681857,7/15/2014 16:32:33,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],"for the treatment of depressive patients,",n/a,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 16:41:48,,1323691712,7/15/2014 16:41:14,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],treatment,N/A,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 16:52:31,,1323703618,7/15/2014 16:52:00,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[TREATS],[TREATS],treatment,N/A,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 16:57:10,,1323708706,7/15/2014 16:56:54,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],"treatment of depressive patients,",n/a,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 17:21:39,,1323728105,7/15/2014 17:21:23,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[TREATS],[TREATS],treatment,N/A,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 17:36:04,,1323739320,7/15/2014 17:35:37,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],treatment,N/A,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 18:05:37,,1323764031,7/15/2014 18:05:10,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],TRICYCLIC ANTIDEPRESSANT treatment DELUSIONAL DEPRESSION,N/A,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 18:21:27,,1323769561,7/15/2014 18:21:03,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[TREATS],[TREATS],ANTIDEPRESSANT,N/A,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 18:30:53,,1323773457,7/15/2014 18:30:12,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[TREATS],[TREATS],TRICYCLIC ANTIDEPRESSANT for the treatment of DELUSIONAL DEPRESSION,n/a,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 18:41:50,,1323777945,7/15/2014 18:40:47,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[IS_A],[IS_A],whether should be designated as a,because  it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232647,7/15/2014 18:55:06,,1323784943,7/15/2014 18:54:07,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,123,26,143,50,1,RO-may_treat,908308-FS1,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
503232648,7/15/2014 14:40:45,,1323602198,7/15/2014 14:40:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],use,na,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 14:47:43,,1323604965,7/15/2014 14:47:34,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],conditions,N/A,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 14:56:42,,1323608355,7/15/2014 14:56:13,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[PREVENTS],[PREVENTS],prevention,N/A,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 15:08:04,,1323613341,7/15/2014 15:07:50,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],GANCICLOVIR for prevention of CMV INFECTION,N/A,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 15:23:30,,1323621902,7/15/2014 15:23:01,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],is the use of GANCICLOVIR for prevention of CMV INFECTION,N/A,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 15:38:23,,1323632592,7/15/2014 15:37:48,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],prevention of,N/a,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 16:18:27,,1323664188,7/15/2014 16:17:44,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS],[PREVENTS],for prevention of,N/A,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 16:37:01,,1323686028,7/15/2014 16:36:35,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[PREVENTS],[PREVENTS],for prevention of,na,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 16:40:55,,1323690759,7/15/2014 16:40:42,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PREVENTS],[PREVENTS],prevention,N/A,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 16:42:46,,1323692725,7/15/2014 16:41:12,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PREVENTS],[PREVENTS],prevention,n/a,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 16:42:48,,1323692728,7/15/2014 16:42:22,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[PREVENTS],[PREVENTS],prevention,N/A,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 18:16:27,,1323767866,7/15/2014 18:16:03,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[PREVENTS],[PREVENTS],GANCICLOVIR for prevention of CMV INFECTION,n/a,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 18:28:14,,1323772491,7/15/2014 18:26:56,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[PREVENTS],[PREVENTS],use of GANCICLOVIR for prevention of CMV INFECTION,N/A,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 18:55:59,,1323785415,7/15/2014 18:55:55,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232648,7/15/2014 21:57:51,,1323860960,7/15/2014 21:57:22,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],research,NONE,123,93,135,104,1,RO-may_prevent,907219-FS1,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
503232649,7/15/2014 14:45:05,,1323603861,7/15/2014 14:44:32,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],proven to be,na,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 14:54:44,,1323607610,7/15/2014 14:54:01,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was biopsy proven to be,N/A,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 15:22:08,,1323620944,7/15/2014 15:21:37,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],biopsy proven to be,N/A,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 15:35:11,,1323630115,7/15/2014 15:34:39,instagc,1.0,18960682,GBR,"","",86.29.147.112,[NONE],[NONE],N/a,Separate conditions in the same patient,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 15:36:24,,1323631140,7/15/2014 15:35:56,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was biopsy proven to be,[DIAGNOSE_BY_TEST_OR_DRUG],19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 15:40:12,,1323633955,7/15/2014 15:39:42,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/a,Separate terms,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 16:34:15,,1323682704,7/15/2014 16:33:53,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],proven to be,N/A,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 16:45:24,,1323695701,7/15/2014 16:44:26,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],proven to be,n/a,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 17:08:31,,1323720254,7/15/2014 17:06:44,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",BILATERAL GROIN ADENOPATHY proven to be CHRONIC LYMPHOCYTIC LEUKEMIA,N/A,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 17:34:35,,1323737983,7/15/2014 17:33:55,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[IS_A],[IS_A],be,n/a,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 17:54:06,,1323756777,7/15/2014 17:53:30,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],metastatic melanoma,n/a,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 18:16:02,,1323767703,7/15/2014 18:14:56,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],BILATERAL GROIN ADENOPATHY was biopsy proven to be CHRONIC LYMPHOCYTIC LEUKEMIA,n/a,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 18:29:11,,1323772923,7/15/2014 18:29:05,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],GROIN,n/a,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 18:33:04,,1323774156,7/15/2014 18:32:19,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],proven to metastatic melanoma and CHRONIC LYMPHOCYTIC,N/A,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232649,7/15/2014 18:58:00,,1323786551,7/15/2014 18:57:55,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,19,94,44,122,-1,RO-disease_may_have_finding,902567-FS1,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
503232650,7/15/2014 14:48:08,,1323605117,7/15/2014 14:47:39,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the,na,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 14:56:59,,1323608485,7/15/2014 14:56:08,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",presented with,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 14:59:18,,1323609352,7/15/2014 14:58:59,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patient with SPLENOMEGALY and HAIRY CELL LEUKEMIA,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 15:14:18,,1323616403,7/15/2014 15:13:47,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],and the leukemic phase of,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 16:35:56,,1323684768,7/15/2014 16:35:10,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 16:36:00,,1323684808,7/15/2014 16:35:38,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 16:44:26,,1323694473,7/15/2014 16:44:07,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 16:54:32,,1323705697,7/15/2014 16:53:47,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and presented,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 17:06:42,,1323718683,7/15/2014 17:05:16,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[NONE],[NONE],N/A,"These two conditions are present in the same patient, but it isn't clear if they are otherwise related.",24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 17:38:00,,1323741250,7/15/2014 17:37:39,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 17:43:58,,1323746604,7/15/2014 17:43:25,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA,n/a,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 17:45:32,,1323748230,7/15/2014 17:45:18,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],SPLENOMEGALY,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 17:45:51,,1323748668,7/15/2014 17:44:38,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],presented with,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 17:56:00,,1323758881,7/15/2014 17:55:12,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232650,7/15/2014 18:25:48,,1323771393,7/15/2014 18:25:09,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count,N/A,24,63,35,82,-1,RO-disease_has_finding,901599-FS1,"A patient with moderate SPLENOMEGALY and the leukemic phase of HAIRY CELL LEUKEMIA presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",SPLENOMEGALY,HAIRY CELL LEUKEMIA
503232651,7/15/2014 14:43:44,,1323603316,7/15/2014 14:43:03,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],can be,N/A,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 14:55:25,,1323607817,7/15/2014 14:54:34,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],three conclusions,N/A,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 15:24:14,,1323622385,7/15/2014 15:23:56,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],can be a,N/A,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 15:28:28,,1323625254,7/15/2014 15:28:14,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PRIMARY LESION; RENAL LYMPHOMA,N/A,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 15:50:28,,1323641637,7/15/2014 15:49:43,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[IS_A],[IS_A],can be a,n\a,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 17:16:30,,1323725524,7/15/2014 17:15:57,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],can be,N/A,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 17:39:02,,1323742220,7/15/2014 17:38:42,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,Na,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 18:08:46,,1323765263,7/15/2014 18:07:46,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",PRIMARY LESION; primary RENAL LYMPHOMA will develop,N/A,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 18:31:08,,1323773557,7/15/2014 18:30:24,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[IS_A],[IS_A],renal lymphoma can be a PRIMARY LESION;,N/A,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 18:37:56,,1323776049,7/15/2014 18:36:45,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[CAUSES],[CAUSES],almost all patients,can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 18:41:07,,1323777591,7/15/2014 18:40:15,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],is reasonable assume renal lymphoma can a PRIMARY LESION; almost all patients primary,N/A,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 18:53:14,,1323783916,7/15/2014 18:52:39,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],three conclusions have been drawn: PRIMARY LESION; RENAL LYMPHOMA,N/A,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 21:48:54,,1323857630,7/15/2014 21:48:19,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],renal lymphoma can be a PRIMARY LESION;,n/a,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 21:56:38,,1323860438,7/15/2014 21:55:17,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[PART_OF],[PART_OF],can be a,n/a,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232651,7/15/2014 22:08:36,,1323866021,7/15/2014 22:07:37,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[LOCATION],[LOCATION],LESION;,NONE,108,157,121,171,1,RO-disease_has_finding,901633-FS1,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
503232652,7/15/2014 14:49:02,,1323605463,7/15/2014 14:48:33,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],specific allergic diseases,na,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 15:00:24,,1323609782,7/15/2014 15:00:05,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],"FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis,",N/A,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 15:16:43,,1323617714,7/15/2014 15:15:57,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],specific allergic diseases,N/A,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 15:30:28,,1323626806,7/15/2014 15:28:10,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],specific allergic diseases,N/a,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 15:33:50,,1323629244,7/15/2014 15:33:03,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],of their,n\a,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 16:06:44,,1323654437,7/15/2014 16:06:23,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"entailed (direct or indirect),",asd,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 16:58:31,,1323710308,7/15/2014 16:57:59,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[PART_OF],[PART_OF],FAMILY ATOPIC HISTORY,na,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 17:13:49,,1323724107,7/15/2014 17:13:24,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[OTHER],[OTHER],specific allergic,N/A,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 17:48:02,,1323750678,7/15/2014 17:47:22,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",specific allergic diseases chronic cough asthma.,n/a,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 18:00:13,,1323761820,7/15/2014 17:59:48,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[PART_OF],[PART_OF],specific allergic diseases,n/a,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 19:25:19,,1323800578,7/15/2014 19:23:44,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[IS_A],[IS_A],FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS,N/A,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 20:10:45,,1323818689,7/15/2014 20:09:59,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",specific allergic diseases,N/A,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 20:48:54,,1323834045,7/15/2014 20:48:26,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],analysis,N/A,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 21:50:00,,1323858009,7/15/2014 21:49:30,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS,n/a,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232652,7/15/2014 22:01:02,,1323862563,7/15/2014 22:00:43,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],asthma.,NONE,105,55,121,76,-1,RO-cause_of,900149-FS1,"This entailed further analysis of their birth history, FAMILY ATOPIC HISTORY specific allergic diseases (ALLERGIC RHINITIS atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",ALLERGIC RHINITIS,FAMILY ATOPIC HISTORY
503232653,7/15/2014 15:04:50,,1323611974,7/15/2014 15:04:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]","treatment, prevented",Na,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 15:06:58,,1323612957,7/15/2014 15:06:43,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],"MAJOR DEPRESSION treatment, PAROXETINE",N/A,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 15:36:23,,1323631131,7/15/2014 15:36:03,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],"to treatment,",N/A,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 15:44:10,,1323636957,7/15/2014 15:43:20,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]","who responded to treatment, long term maintenance treatment prevented recurrence of depression.",N/A,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 16:50:09,,1323701073,7/15/2014 16:49:42,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment with,n/a,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 17:43:31,,1323746311,7/15/2014 17:42:42,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],"responded to treatment,",N/A,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 17:45:06,,1323747853,7/15/2014 17:44:33,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PREVENTS],[PREVENTS],prevented,N/A,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 18:08:17,,1323765046,7/15/2014 18:06:13,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[TREATS],[TREATS],treatment with PAROXETINE,N/A,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 18:41:35,,1323777820,7/15/2014 18:40:50,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[TREATS],[TREATS],In patients with MAJOR DEPRESSION long term maintenance treatment with PAROXETINE prevented recurrence depression.,n/a,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 18:55:21,,1323785084,7/15/2014 18:55:15,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 19:04:27,,1323790324,7/15/2014 19:04:00,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treatment with,not applicable,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 19:56:22,,1323812548,7/15/2014 19:55:02,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[PREVENTS],[PREVENTS],prevented recurrence,N/A,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 20:37:35,,1323829509,7/15/2014 20:37:15,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],"responded to treatment,",N/A,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 21:42:44,,1323855604,7/15/2014 21:42:30,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],long term maintenance treatment,n/a,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232653,7/15/2014 22:09:23,,1323866301,7/15/2014 22:08:58,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],long term maintenance treatment with,n/a,36,118,51,128,1,RO-may_treat,907618-FS1,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
503232654,7/15/2014 14:42:20,,1323602820,7/15/2014 14:41:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tested with diagnosed as,N/A,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 14:47:22,,1323604865,7/15/2014 14:47:13,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SYMPTOM],[SYMPTOM],was,N/A,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 14:57:23,,1323608643,7/15/2014 14:57:05,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[CAUSES],[CAUSES],positive;,na,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 15:48:44,,1323640334,7/15/2014 15:48:17,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tested with,N/A,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 16:17:10,,1323663013,7/15/2014 16:16:21,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was diagnosed as,N/A,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 16:35:14,,1323683853,7/15/2014 16:34:13,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed as,na,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 16:36:13,,1323685092,7/15/2014 16:36:02,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,N/A,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 17:12:40,,1323723428,7/15/2014 17:11:49,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],tested with TUBERCULIN,na,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 17:40:08,,1323743281,7/15/2014 17:39:51,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were,Na,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 17:57:46,,1323760519,7/15/2014 17:57:10,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[MANIFESTATION],[MANIFESTATION],TUBERCULIN diagnosed TUBERCULOSIS,N/A,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 18:13:37,,1323766871,7/15/2014 18:13:03,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[OTHER],[OTHER],TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,N/A,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 18:26:48,,1323771814,7/15/2014 18:26:40,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],tested,n/a,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 19:01:02,,1323788646,7/15/2014 19:00:33,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tested with diagnosed as,not applicable,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 20:11:04,,1323818828,7/15/2014 20:10:01,clixsense,1,26649250,GBR,B7,Bristol,79.71.112.51,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tested with,n/a,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232654,7/15/2014 20:46:58,,1323833263,7/15/2014 20:46:40,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tested with TUBERCULIN,N/A,91,44,102,54,1,RO-may_diagnose,906806-FS1,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
503232655,7/15/2014 14:59:43,,1323609490,7/15/2014 14:58:39,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",patients on maintenance haemodialysis were given,N/A,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 15:00:13,,1323609686,7/15/2014 14:59:42,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",were given,N/A,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 15:34:15,,1323629536,7/15/2014 15:33:51,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],were given,n\a,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 15:34:41,,1323629819,7/15/2014 15:34:20,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],were given 320 mg QUININE SULPHATE,N/A,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 15:49:11,,1323640655,7/15/2014 15:48:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],were given,n/a,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 16:16:49,,1323662648,7/15/2014 16:16:30,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],each dialysis,asd,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 16:40:59,,1323690821,7/15/2014 16:40:37,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],were given 320 mg,ha,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 16:51:06,,1323702002,7/15/2014 16:50:37,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[TREATS],[TREATS],were given,N/A,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 16:55:18,,1323706455,7/15/2014 16:54:55,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],were given 320 mg,n/a,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 17:35:36,,1323738944,7/15/2014 17:35:11,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],patients were given,N/A,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 17:59:21,,1323761489,7/15/2014 17:58:47,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],MUSCLE CRAMPS given QUININE SULPHATE,N/A,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 19:13:52,,1323795056,7/15/2014 19:10:43,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],MUSCLE CRAMPS were given 320 mg QUININE SULPHATE,N/A,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 21:33:50,,1323852760,7/15/2014 21:32:50,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[OTHER],[OTHER],were given 320 mg,Treated by,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 21:47:36,,1323857234,7/15/2014 21:47:07,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],were given QUININE SULPHATE each dialysis for a period of 12 weeks.,n/a,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232655,7/15/2014 21:58:36,,1323861310,7/15/2014 21:57:52,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MUSCLE CRAMPS,NONE,57,89,69,105,1,RO-may_prevent,907060-FS1,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
503232656,7/15/2014 14:48:31,,1323605293,7/15/2014 14:48:10,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],observed in,na,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 14:49:16,,1323605534,7/15/2014 14:49:07,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],translocated,N/A,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 15:01:00,,1323610038,7/15/2014 15:00:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],observed,Na,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 15:10:37,,1323614545,7/15/2014 15:09:52,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],observed in,N/A,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 15:27:16,,1323624386,7/15/2014 15:26:54,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed in,[DIAGNOSE_BY_TEST_OR_DRUG],230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 15:39:46,,1323633634,7/15/2014 15:37:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],observed in,n/a,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 15:42:37,,1323635721,7/15/2014 15:41:49,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[PART_OF],[PART_OF],observed in,N/A,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 16:50:06,,1323700986,7/15/2014 16:49:22,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],observed in,na,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 16:54:22,,1323705423,7/15/2014 16:53:46,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],observed in,n/a,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 17:31:18,,1323735051,7/15/2014 17:30:44,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[MANIFESTATION],[MANIFESTATION],observed in,n/a,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 18:27:37,,1323772205,7/15/2014 18:27:31,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],observed,n/a,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 18:58:07,,1323786630,7/15/2014 18:58:01,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 19:49:25,,1323810252,7/15/2014 19:47:32,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]",observed in,N/A,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 22:06:20,,1323864914,7/15/2014 22:05:34,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],observed in,n/a,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232656,7/15/2014 22:37:09,,1323879562,7/15/2014 22:36:16,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],BCL 2 GENE observed in FOLLICULAR LYMPHOMAS,N/A,230,207,249,217,-1,RO-has_manifestation,906095-FS1,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
503232657,7/15/2014 15:04:16,,1323611698,7/15/2014 15:03:55,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],successful closure,Na,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 15:24:23,,1323622468,7/15/2014 15:24:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the successful,N/A,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 15:28:49,,1323625534,7/15/2014 15:27:41,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],ESOPHAGOBRONCHIAL fistula closure of the FISTULA TRACT,N/A,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 15:35:45,,1323630577,7/15/2014 15:35:30,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],successful closure of,N/a,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 15:43:00,,1323636000,7/15/2014 15:42:12,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],closure of the,n/a,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 15:52:21,,1323643125,7/15/2014 15:51:23,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[LOCATION],[LOCATION],the successful closure of,N/A,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 16:41:20,,1323691198,7/15/2014 16:40:29,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[LOCATION],[LOCATION],of the FISTULA TRACT,N/A,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 16:42:42,,1323692670,7/15/2014 16:41:00,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],fistula and the successful closure of,ha,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 16:52:00,,1323703046,7/15/2014 16:51:28,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],successful closure of,n/a,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 17:17:14,,1323725900,7/15/2014 17:16:50,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],of the,N/A,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 17:44:17,,1323746905,7/15/2014 17:44:02,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],TRACT,N/A,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 18:24:26,,1323770876,7/15/2014 18:24:05,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],closure of the FISTULA TRACT,N/A,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 18:41:29,,1323777759,7/15/2014 18:41:08,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],WITH AN,N/A,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 21:41:27,,1323855160,7/15/2014 21:40:14,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,[PART_OF],[PART_OF],ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT,N/A,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232657,7/15/2014 22:02:13,,1323863074,7/15/2014 22:02:04,neodev,1.0,17344784,GBR,G7,Kingston Upon Thames,80.43.164.136,[CAUSES],[CAUSES],ESOPHAGOBRONCHIAL,NONE,117,18,129,74,-1,RO-has_manifestation,906096-FS1,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
503232658,7/15/2014 14:39:05,,1323601563,7/15/2014 14:38:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],rearrangement,na,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 14:54:13,,1323607414,7/15/2014 14:53:45,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],rearrangement in,N/A,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 15:06:12,,1323612570,7/15/2014 15:05:38,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],GENE rearrangement in patients,N/A,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 15:33:49,,1323629235,7/15/2014 15:33:16,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[IS_A],[IS_A],rearrangement in,[IS_A],91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 15:41:02,,1323634518,7/15/2014 15:40:24,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,[PART_OF],[PART_OF],rearrangement in,N/A,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 16:49:11,,1323699894,7/15/2014 16:48:50,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[MANIFESTATION],[MANIFESTATION],rearrangement in,N/A,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 17:26:47,,1323731231,7/15/2014 17:25:32,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[NONE],[NONE],n/a,No relation found,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 17:42:24,,1323745301,7/15/2014 17:42:06,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GENE rearrangement,N/A,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 18:39:55,,1323777062,7/15/2014 18:39:20,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients,n/a,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 18:57:11,,1323786058,7/15/2014 18:57:05,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 19:18:33,,1323797569,7/15/2014 19:18:04,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[PART_OF],[PART_OF],rearrangement in,not applicable,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 20:53:38,,1323835787,7/15/2014 20:53:20,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],rearrangement in,N/A,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 22:10:40,,1323866954,7/15/2014 22:09:23,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],rearrangement in,n/a,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 22:29:47,,1323875749,7/15/2014 22:28:06,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA,N/A,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232658,7/15/2014 22:52:06,,1323886686,7/15/2014 22:50:55,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA,Causes / Manifestation,91,63,109,73,-1,RO-has_manifestation,906133-FS1,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
503232659,7/15/2014 14:46:12,,1323604348,7/15/2014 14:45:48,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatments,N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 14:48:49,,1323605386,7/15/2014 14:48:28,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treatments management methods.,N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 15:01:38,,1323610427,7/15/2014 15:01:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],"prevention,",N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 15:07:49,,1323613228,7/15/2014 15:07:30,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],FLUORIDE treatments or other CARIES management methods.,N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 15:13:27,,1323615967,7/15/2014 15:13:07,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],treatments,N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 15:28:54,,1323625575,7/15/2014 15:28:00,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[TREATS],[TREATS],treatments,[TREATS],243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 15:37:11,,1323631714,7/15/2014 15:36:47,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],treatments,N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 15:42:44,,1323635790,7/15/2014 15:42:18,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Separate terms,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 15:46:30,,1323638745,7/15/2014 15:46:12,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PREVENTS],[PREVENTS],management methods.,n/a,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 16:51:01,,1323701926,7/15/2014 16:50:46,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],treatments,N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 16:58:36,,1323710459,7/15/2014 16:58:06,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[PREVENTS],[PREVENTS],"prevention,",N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 17:45:46,,1323748522,7/15/2014 17:45:33,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PART_OF],[PART_OF],or other,N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 18:02:40,,1323762737,7/15/2014 18:02:08,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",FLUORIDE treatments CARIES,N/A,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 18:21:44,,1323769641,7/15/2014 18:20:23,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],types of topical FLUORIDE treatments or other CARIES management methods.,n/a,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232659,7/15/2014 18:56:39,,1323785759,7/15/2014 18:56:33,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,243,188,248,196,1,RO-may_prevent,907105-FS1,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
503232660,7/15/2014 14:56:07,,1323608119,7/15/2014 14:55:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",was used,N/A,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 15:02:04,,1323610625,7/15/2014 15:01:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],with,Na,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 15:06:20,,1323612647,7/15/2014 15:05:50,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],3 HEPATOMA patients with ASCITES elemental diet used,N/A,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 15:25:08,,1323622937,7/15/2014 15:24:32,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],HEPATOMA patients with ASCITES,N/A,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 15:25:36,,1323623347,7/15/2014 15:25:08,elite,1.0,28276268,USA,MA,Brighton,24.218.18.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",patients with,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 15:31:38,,1323627558,7/15/2014 15:31:22,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with,N/a,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 16:35:36,,1323684331,7/15/2014 16:35:24,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 16:47:19,,1323697962,7/15/2014 16:46:07,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATOMA patients with ASCITES,na,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 16:56:53,,1323708366,7/15/2014 16:56:33,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 17:37:58,,1323741203,7/15/2014 17:37:33,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[NONE],[NONE],n/a,No relation found.,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 17:43:36,,1323746382,7/15/2014 17:43:28,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],with,N/A,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 17:59:01,,1323761312,7/15/2014 17:57:48,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],with,n/a,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 18:04:26,,1323763599,7/15/2014 18:03:01,clixsense,1.0,24858196,USA,PA,Kingston,96.253.217.126,[MANIFESTATION],[MANIFESTATION],HEPATOMA patients with ASCITES,N/A,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 18:17:19,,1323768174,7/15/2014 18:16:28,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATOMA patients with ASCITES,n/a,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232660,7/15/2014 19:44:16,,1323808590,7/15/2014 19:41:52,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[OTHER],[OTHER],elemental diet,N/A,75,52,81,60,-1,RO-disease_may_have_finding,902970-FS1,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
503232661,7/15/2014 14:41:56,,1323602612,7/15/2014 14:41:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],positive,N/A,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 15:35:43,,1323630578,7/15/2014 15:34:46,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],positive,n/a,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 15:50:06,,1323641329,7/15/2014 15:49:27,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],TUBERCULIN,same,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 16:38:50,,1323688259,7/15/2014 16:37:53,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[IS_A],[IS_A],TUBERCULIN positive,N/A,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 16:39:41,,1323689309,7/15/2014 16:37:02,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and those with previous,na,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 17:15:01,,1323724746,7/15/2014 17:14:26,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM] [CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]",intravenous drug users,n/a,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 17:44:36,,1323747277,7/15/2014 17:43:31,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],prophylaxis should be offered,N/A,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 17:46:58,,1323749724,7/15/2014 17:46:45,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN TUBERCULOSIS,N/A,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 17:47:44,,1323750378,7/15/2014 17:46:34,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[IS_A],[IS_A],primarily to TUBERCULIN positive with previous TUBERCULOSIS,n/a,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 18:01:34,,1323762333,7/15/2014 18:01:14,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],positive,n/a,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 19:23:43,,1323799914,7/15/2014 19:23:02,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN positive patients with previous TUBERCULOSIS,N/A,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 20:38:59,,1323830034,7/15/2014 20:37:57,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],primarily to TUBERCULIN positive previous TUBERCULOSIS,N/A,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 22:24:44,,1323873214,7/15/2014 22:23:50,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TUBERCULIN with previous TUBERCULOSIS,N/A,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 22:58:46,,1323889839,7/15/2014 22:57:12,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN positive TUBERCULOSIS,Associated with,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232661,7/15/2014 23:16:26,,1323899997,7/15/2014 23:15:31,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH] [IS_A] [PART_OF],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",TUBERCULIN positive TUBERCULOSIS,N/A,302,134,313,144,1,RO-may_diagnose,906813-FS1,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to TUBERCULIN positive or anergic patients from high incidence groups, including immigrants from high prevalence countries, intravenous drug users and those with previous TUBERCULOSIS that secondary prophylaxis be withheld from all but very high risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",TUBERCULOSIS,TUBERCULIN
503232662,7/15/2014 14:46:11,,1323604360,7/15/2014 14:46:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],shown,N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 14:50:51,,1323606074,7/15/2014 14:50:31,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],cases of,N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 14:50:59,,1323606146,7/15/2014 14:50:31,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],one SEVERE DYSPLASIA,na,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 15:16:41,,1323617704,7/15/2014 15:14:32,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],three cases of,N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 15:30:11,,1323626600,7/15/2014 15:28:50,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA",N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 16:42:18,,1323692197,7/15/2014 16:41:28,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[IS_A],[IS_A],CIN III SEVERE,N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 17:13:05,,1323723664,7/15/2014 17:12:42,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[IS_A],[IS_A],one case,N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 17:16:21,,1323725461,7/15/2014 17:15:41,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA CIN II (moderate dysplasia),na,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 17:33:55,,1323737524,7/15/2014 17:33:10,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],shown three cases,N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 17:48:45,,1323751402,7/15/2014 17:48:28,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],SEVERE DYSPLASIA,N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 18:40:46,,1323777436,7/15/2014 18:39:52,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[SYMPTOM],[SYMPTOM],three cases of,"has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA",138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 18:45:32,,1323779805,7/15/2014 18:44:46,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],one one case with CIN II and one case with,N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 19:19:21,,1323797996,7/15/2014 19:18:35,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,There is no relation. They are two different diseases.,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 20:48:09,,1323833722,7/15/2014 20:46:58,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],has shown,N/A,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232662,7/15/2014 22:17:30,,1323869984,7/15/2014 22:17:03,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],one one case with,n/a,138,102,153,109,-1,RO-disease_has_finding,901644-FS1,"In five of the 29 false negative cases with dysplasia histological follow up has shown three cases of CIN III (two carcinoma in situ, one SEVERE DYSPLASIA one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",SEVERE DYSPLASIA,CIN III
503232663,7/15/2014 14:48:12,,1323605150,7/15/2014 14:47:37,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],ALLERGY,N/A,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 15:25:28,,1323623223,7/15/2014 15:24:44,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],manifestations,N/a,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 15:44:20,,1323637107,7/15/2014 15:43:23,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION],[MANIFESTATION],in the absence of clinical manifestations of,[MANIFESTATION],102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 16:37:28,,1323686571,7/15/2014 16:35:57,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",was detected in,N/A,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 16:43:09,,1323693117,7/15/2014 16:42:52,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[IS_A],[IS_A],manifestations,N/A,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 16:54:06,,1323705158,7/15/2014 16:52:01,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CONTRAINDICATES],[CONTRAINDICATES],to thi antibiotic in the absence of clinical manifestations of,na,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 17:33:39,,1323737190,7/15/2014 17:33:01,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],antibiotic,n/a,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 18:11:35,,1323766241,7/15/2014 18:10:02,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERSENSITIVITY in the absence of ALLERGY,n/a,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 18:24:04,,1323770758,7/15/2014 18:23:13,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],HYPERSENSITIVITY to antibiotic in the absence of clinical manifestations of ALLERGY,N/A,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 18:38:52,,1323776561,7/15/2014 18:38:00,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM] [OTHER],"[SYMPTOM]
[OTHER]",thi antibiotic in the absence of clinical manifestations of,N/A,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 20:42:08,,1323831253,7/15/2014 20:41:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],to thi antibiotic in the absence of clinical manifestations of,N/A,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 22:34:43,,1323878288,7/15/2014 22:34:08,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERSENSITIVITY in the absence of ALLERGY was detected,N/A,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 22:57:10,,1323889150,7/15/2014 22:56:01,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CONTRAINDICATES],[CONTRAINDICATES],HYPERSENSITIVITY antibiotic absence clinical manifestations of ALLERGY was detected,Contraindicates,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/15/2014 22:59:54,,1323890358,7/15/2014 22:59:08,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[MANIFESTATION],[MANIFESTATION],HYPERSENSITIVITY to thi antibiotic absence clinical manifestations of ALLERGY was detected,N/A,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232663,7/16/2014 00:01:02,,1323923655,7/16/2014 00:00:22,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],absence,n/a,102,182,117,189,-1,RO-cause_of,900315-FS1,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
503232664,7/15/2014 14:48:34,,1323605294,7/15/2014 14:47:50,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],evidence,N/A,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 14:48:38,,1323605305,7/15/2014 14:48:27,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],enzyme,N/A,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 15:21:18,,1323620430,7/15/2014 15:21:02,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],measured by enzyme immunoassay of,N/A,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 15:33:04,,1323628676,7/15/2014 15:32:41,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],was measured by enzyme,N/a,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 15:40:51,,1323634420,7/15/2014 15:40:13,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],measured by,N/A,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 15:52:17,,1323643073,7/15/2014 15:51:40,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],INFECTION,n/a,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 16:18:12,,1323663948,7/15/2014 16:17:39,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],VARICELLA ZOSTER VIRUS INFECTION,asd,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 16:44:24,,1323694425,7/15/2014 16:43:37,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was measured by enzyme immunoassay of,na,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 17:54:31,,1323757249,7/15/2014 17:54:07,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",enzyme immunoassay,n/a,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 18:25:30,,1323771285,7/15/2014 18:25:12,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],evidence,n/a,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 18:33:46,,1323774402,7/15/2014 18:33:18,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],VARICELLA ZOSTER VIRUS INFECTION was measured by VARICELLA ZOSTER VIRUS,N/A,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 18:37:58,,1323776086,7/15/2014 18:37:34,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was measured,N/A,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 18:56:26,,1323785649,7/15/2014 18:56:20,prodege,1.0,12944140,GBR,C8,Thornton Heath,92.21.6.167,[NONE],[NONE],na,na,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 20:06:55,,1323817101,7/15/2014 20:06:06,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],evidence of,N/A,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
503232664,7/15/2014 20:41:22,,1323830984,7/15/2014 20:40:54,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],measured by enzyme immunoassay,N/A,22,22,43,54,-1,RO-has_causative_agent,903703-FS1,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
